Speaker Bios

Allan Adler
Kathy Anderson

Christopher M. Arena
Erika Arner
Elizabeth Bachert
Chris Bailey
Richard Baker
Jonathan Band
Brent Bankosky
Theresa Baus
Kurt Becker
Stan Benda
Oliver Bennett
Louis P. Berneman
Martin Birkhofer
Michael Bishop
Kevin Bitterman
Ben Bonifant
Daniel Broderick
Jim Burger
James Burns
Angela Bylancik
Lisa Cameron
Susan A. Capello
Frederick Cartwright
Daniel Castro
Cheryl Cejka
Hector Chagoya
Guy Chambers
Linda Chao
Elizabeth Chien-Hale
Kimberly S. Chotkowski
Brad Close
Jason Cole
Lynda Covello
Hal Craig
Anthony del Campo
Patrick Desmond
Lisa Dhar
Amit Dhawan
Roberto Dini
Don Drinkwater
Ben du Pont
Halina Dziewit
Mark Edwards
Linda Egger
William Elkington
Steven M. Ferguson
Christine T. Fischette
Allison Formal
Lauren Foster
David Fraser
Brian Frizzell
Paul Gallagher
Patrick G. Gattari
Paul Germeraad
Adam Golden
Michael Graham
Paul V. Greco
Richard Greeley
Kamal Hassin
Jaime Heins
Elias Hinckley
Yorikatsu Hohokabe
Niels Hölder
Chris Holman
Mark S. Holmes
Jackie Hutter
Mason (Skip) Irving, III
David Jarczyk
Dave Johnson
Gary Jones
Paul Jones
Syed Kazmi
John Keagy
George Keller
Bill Killian
Peter B. Kramer
Katharine Ku
George Kyroudis
Dooyong Lee
Nick Lee
Jeff Leedom
Reid Leonard
Jason Levin
Russell Levine
Steven D. Levitt
Terry Ludlow
Jason Lye
Robert MacKenzie
Todd MacLaughlan
Robert S. MacWright
Jeet Mahal
J. Derek Mason
Damon C. Matteo
James A. McCarthy
Andy McGee
Eileen McMahon
Thomas Meagher
Stewart Mehlman
Rebecca Menapace
Bernd Merkl
Jeremy D. Middleton
Lesley Millar
G. John Mohr
Tanya K. Moore
Christopher Morrison
Charles Murray
Charles R. Neuenschwander
Fiona Nicolson
Chris Noble
Brian O'Shaughnessy
Stasia Ogden
Cat Oyler
Wendy Pan
Daniel Papst
John Paul
Clay Phillips
Ruth Plager
Michael Plonka
Casey Porto
Stephen Potter
Guy Proulx
Linda Pullan
Dennis Purcell
John T. Ramsay
Mohan Rao
Robin Rasor
Matthew J. Raymond
John Reid
Thomas Rein
John F. Ritter
Art Rose
Jean Rumsfield
Pradip 'Pete' Sahu
Fernando J. Sallés
Edward C. Saltzman
Michael R. Samardzija
Larry Saret
Joshua Sarnoff
Andrew Schapals
Aaron Schuchart
Rachael S. Schwartz
Katherine (Kate) Shore
Ida C. Shum
Lauren Silverman
Robin Sitver
Gene Slowinski
Craig Smith
Jeff Snell
James Sobieraj
Vanita Spaulding
Susan L. Stoddard
Philip Strassburger
Nancy Sullivan
Elliot Swan
Christopher G. Talbot
Richard Lawton Thurston
David Tollen
Steven Tregay
Pannie Trifillis
Jan Twombly
Larry Udell
Ramani Varanasi
Edna Vassilovski
Allen Vaughn
Anthony P. Venturino
Erik Verbraeken
John Veschi
James Vlazny
Glenn Von Tersch
Angela Wenninger
Brandon Williams
Katharine Wolanyk
Mary Woodford
Donald Wright
Junichi Yamazaki
Jordan Yarett
Carolyne Zimmermann

Allan Adler
Since 1996, VP for Legal & Government Affairs for the Association of American Publishers. Before that, partner at Washington, D.C. communications law firm Cohn & Marks (1989-1996) and Legislative Counsel for American Civil Liberties Union (1981-1989). JD from The George Washington University (1978); BA in History from SUNY Binghamton (1974).

[back to top]

Kathy Anderson
Kathy Anderson J.D., licensed to practice in MN and 8th Circuit Federal Court.  Former Assistant County Attorney in Rochester, MN.  Currently a consultant in the Department of Public Affairs at Mayo Clinic, Rochester MN.  For the past 6 years  works exclusively with Mayo's Office of Intellectual Property handling business and medial relations.

[back to top]

Christopher M. Arena
Chris is currently a partner in the Atlanta office of Woodcock Washburn, a national intellectual property law firm.  He is the former Chief Intellectual Property Counsel at Cingular Wireless where he was responsible for all aspects of intellectual property. Prior to that, he was Chief Patent Counsel at BellSouth Corporation and a founding officer of the BellSouth Intellectual Property Group of companies. Before becoming an attorney, he spent eight years as systems engineer and engineering manager for IBM Corporation in Manassas, Va. This extensive and varied background, including his eleven years as an in-house attorney, has given Chris broad and somewhat unique expertise in all areas of IP law and business. He has particular skill in transactional matters, especially asset acquisition, management and licensing transactions. His focus is on the business implications of intellectual property, where he applies his skills to help clients achieve greater value for their businesses through strategic use of intellectual property.

Chris is the co-author of The Business of Intellectual Property (Oxford University Press, 2008). He holds a bachelor's degree in electrical engineering from the University of Notre Dame and a law degree from George Mason University. He is admitted to practice law in Georgia and Pennsylvania as well as before the U.S. Patent and Trademark Office.

[back to top]

Erika Arner
Erika Arner is an associate in the Electrical Practice Group at Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. Her practice includes patent prosecution management, client counseling, and litigation with an emphasis on electronic technology, computer software and the Internet. Ms. Arner has helped clients of all sizes to establish and grow patent portfolios, design and implement procedures to protect intellectual capital, and formulate company-wide IP strategies and policies.
Ms. Arner has provided opinions on patentability, infringement, and validity of patents and drafted or overseen the drafting of over one hundred patent applications for business method, electrical, telecommunications, and software-based technologies.

Ms. Arner graduated cum laude from the Washington and Lee University School of Law in 1999 and earned her bachelor of science degree in computer science from the College of William and Mary in 1993. She is admitted to practice in Virginia and the District of Columbia. While in law school, Ms. Arner served as Articles Editor for the Environmental Law Digest of the Virginia Bar Association. She also worked at the University's legal practice clinic. Prior to law school, Ms. Arner gained her initial exposure to patent law serving as a clerk with a large patent law firm in Arlington, Virginia.

[back to top]

Elizabeth Bachert
Elizabeth Bachert is a Sr. Director, Worldwide Business Development at Pfizer in New London, CT.  She is responsible for the search and evaluation of clinical stage oncology business opportunities for Pfizer's Oncology Business Unit.  She has contributed to several oncology-focused business transactions including the Serenex and Coley acquisitions and licenses to assets at Coley and Celldex.     Beth began her career at Pfizer in 1994 in Pfizer's Global R&D operations in Groton, CT as a Research Scientist in the Drug Metabolism Department, where she led the design and conduct of pre-clinical PK and PK/PD studies for projects in the Cancer, Respiratory, Immunology, Inflammation, and Infectious Diseases areas. Beth holds a BS and PhD in Pharmaceutics from the University at Buffalo.  

[back to top]

Chris Bailey
Chris Bailey has spent his career in Asia, predominantly China, helping multinational companies manage their IPR in the region, starting in 1995, when China's IPR regime was still in its early stages. Chris speaks fluent Mandarin and currently heads Rouse's office in the Pearl River Delta. Chris was one of the creators of Rouse's CIELA litigation analysis tool (www.ciela.cn) which is a pioneering statistical database of IP rulings from China's courts. Chris also heads Rouse's IAM practice in China and lead Rouse to be one of the first foreign firms to sign cooperation agreements with China's technology exchanges.

[back to top]

Richard Baker
Richard Baker, CLP, is the Director of Intellectual Property Licensing for 3Com Corporation.  Since joining 3Com, Mr. Baker has been involved in a number of licensing projects and in the management of existing licenses for 3Com.

Rich Baker is also running for a seat in the United States House of Representatives for the Massachusetts 6th Congressional District (North of Boston).

Prior to joining 3Com, Mr. Baker was the Director of Intellectual Property at Schneider Automation. Mr. Baker is an inventor on 15 patents in the Web, embedded Ethernet, and business method areas for his work at Schneider.

Mr. Baker's graduate studies include Intellectual Property at Franklin Pierce Law Center and Computer Science at Harvard University. He holds a bachelor's degree in Computer Science and English as a dual major at the University of New Hampshire.

Mr. Baker resides with his wife and son in West Newbury, Massachusetts.

[back to top]

Jonathan Band
Jonathan Band helps shape the laws governing intellectual property and the Internet through a combination of legislative and appellate advocacy.  He has represented clients with respect to the drafting of the Digital Millennium Copyright Act (DMCA); database protection legislation; the Uniform Computer Information Transactions Act; and other federal and state statutes relating to intellectual property and the Internet.  He complements this legislative advocacy by filing amicus briefs in significant cases related to these provisions.  Mr. Band's deep substantive knowledge of the application of intellectual property law to information technology permits him to counsel clients on complex copyright issues.   Mr. Band is an adjunct professor at the Georgetown University Law Center, and has written extensively on intellectual property and the Internet, including the book Interfaces on Trial and over 60 articles.   Mr. Band received a B.A., magna cum laude, Phi Beta Kappa, in 1982 from Harvard College, and a J.D. from Yale Law School in 1985. From 1985 to 2005, Mr. Band worked at the Washington, D.C., office of Morrison & Foerster LLP, including thirteen years as a partner. Mr. Band established his own law firm in May, 2005.   

[back to top]

Brent Bankosky
Brent Bankosky joined Takeda Pharmaceuticals North America, Inc. in 2008 and transitioned to Takeda Pharmaceuticals International, Inc. in 2009.  Mr. Bankosky holds the position of Director, Strategic Transactions within the Global Licensing & Business Development organization at Takeda.  Mr. Bankosky is responsible for leading licensing transactions in the Metabolic Disease, Cardiovascular Disease, and Obesity space.  Mr. Bankosky also leads the Strategic Transactions team that is responsible for out-licensing and pipeline finance transactions. Mr. Bankosky holds a B.S. and M.B.A. from Pennsylvania State University and a M.S. from Lehigh University.

[back to top]

Theresa A. Baus, Ph.D.
Theresa A. Baus, Ph.D. , is currently Head of the Technology Partnership Enterprise Office (TPEO) at the Naval Undersea Warfare Center in  Newport, RI. The TPEO encompasses all aspects of partnering activities with industry, academia, state and local governments and other federal laboratories. The TPEO is active in the Navy and DOD SBIR programs, Industrial R&D programs as well as technology transfer efforts including Cooperative Research and Development Agreements (CRADAs), Work For Private Party agreements, patent licensing and Education Partnerships.

[back to top]

Kurt Becker
Kurt Becker, Vice President, Legal Affairs for Intellectual Ventures.  Graduated from the University of Michigan Law School in 1986.  Relevant to this panel, Kurt began his legal career doing insolvency litigation and then became an IP and technolgoy licensing attorney in the early 1990s.  Kurt became a partner in Perkins Coie LLP in Seattle in 1993.  Beginning in 2006, for more than 4 years, Kurt helped build IV's patent acquisition process.   Among other acquisition, Kurt has experience (and war stories) from acquisitions of assets from defunct or insolvent companies in the United States, Canada, Israel, France, Germany, Sweden, Italy, and England.  He now leads legal support for IV's burgeoning sales of patents assets.

[back to top]

Stan Benda
Dr. Stan Benda is Counsel with Sim McBurney in Toronto.  He received his Ph.D. in law on the Labeling of Genetically Modified Foods.  He previously was senior counsel with Justice Canada where he acted for Agriculture Canada, Intellectual Property Branch / Research Branch (technology transfer /licensing) and Agriculture Canada Multilateral Science Relations (animal / plant / biodiversity genetic treaties). He has written articles on: IP rights & the regulatory regime concerning agricultural crops; the regulation of genetically modified crops; the precautionary principle; Cartagena Protocol; and technology transfer in government.  He is adjunct faculty at both Osgoode Hall Law School, and Ryerson University Business School.  He is a member of the American Agricultural Law Assoc., the Licensing Executive Society, the Canadian Health Licensing Assoc. and an associate with the Intellectual Property Institute of Canada. 

[back to top]

Oliver Bennett
Mr. Bennett is Counsel in the intellectual property litigation department at Kaye Scholer LLP.  An experienced trial lawyer, Mr. Bennett has litigated several jury and bench trials on complex patent infringement cases across a variety of technologies, including biotechnology, medical devices, consumer electronics and internet-based technologies.  Mr. Bennett was Fulbright Scholar at Harvard Law School, where he studied the relationship between intellectual property laws and technological innovation.  

[back to top]

Louis P. Berneman
Louis Berneman heads Texelerate, LLC, a technology transfer consultancy focusing on assisting institutions, investors, entrepreneurs and companies with licensing transactions, royalty monetization, and creating and financing start ups. His current principal engagements are as Partner, Osage University Partners and as Member, Strategic Advisory Board, Cowen Healthcare Royalty Partners. Previously, Mr. Berneman was managing director of the Center for Technology Transfer at the University of Pennsylvania. Mr. Berneman is a Past President of AUTM) and a former Vice President and Trustee of LES USA & Canada. He has been involved in intellectual property licensing, business development and entrepreneurial activities for more than 25 years. He is a Certified Licensing Professional. Mr. Berneman has testified as an expert on licensing issues in intellectual property litigation matters. He holds a baccalaureate degree from the Pennsylvania State University, a teaching credential from University of California at Santa Barbara, and masters and doctoral degrees from Teachers College, Columbia University.

[back to top]

Martin Birkhofer
Martin J. Birkhofer, MD, is Vice-President, Search and Evaluation, Bristol Myers Squibb, Research and Development.  In this position Dr. Birkhofer and his team oversee the evaluation and diligence efforts for all M&A and licensing activities across the therapeutic areas of interest to the company.   Since joining Bristol-Myers Squibb in 1994, Dr. Birkhofer has worked in early Phase drug development as Executive Director, Clinical Pharmacology, based in Princeton, N.J. and has also worked internationally as Executive Director, Oncology Clinical Research, Europe, based at the Bristol-Myers Squibb facility in Waterloo, Belgium.    In late 1998 Dr. Birkhofer was appointed Vice President Product Development Champion for Erbitux, and co-lead the Erbitux development team through the successful filing and launch of the product in advanced colon cancer and locally advanced head and neck cancer.

[back to top]

Michael Bishop
Michael Bishop is General Counsel of AT&T Intellectual Property Corporation, in Atlanta, Georgia. He formerly served as Chief IP Counsel for BellSouth Corporation. Prior to joining BellSouth, Mr. Bishop practiced law at King & Spalding, in Atlanta. Mr. Bishop received his juris doctor in 1990 from The George Washington University Law School, Washington, D.C. , and is a 1985 graduate of the University of Florida, Gainesville, Florida, with a B.A. , History, magna cum laude. Mr. Bishop attended graduate school in history at the University of York, York, UK, 1986 - 87. He is a native of Jacksonville, Florida.

[back to top]

Kevin Bitterman
Kevin J. Bitterman is a Principal at Polaris Venture Partners.  Kevin joined Polaris in 2004 and focuses on investments in the life sciences.  Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School.  His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.  Kevin has authored papers in several top tier journals, is an inventor on multiple patents and is a cofounder of Genocea Biosciences and Sirtris Pharmaceuticals (GSK).  Kevin currently represents Polaris as a Director of Biolex Therapeutics, EPacing Inc., Follica Inc., Genocea Biosciences, Kala Pharmaceuticals, Parasol Therapeutics, and Taris Biomedical.  Additionally, Kevin is a Board Observer to Pulmatrix Inc.

[back to top]

Ben Bonifant
Ben Bonifant is an experienced consultant to leaders of global pharmaceuticals and biotechnology organizations and to decision makers of large private equity funds. Mr. Bonifant has been a management consultant for more than fourteen years. His perspectives on developments in the life sciences market are frequently published in industry and strategy journals. Recent by-lined articles have appeared in Pharmaceutical Executive, Chemical Specialties, and Business Horizons. He is the author of the chapter, "Market Segmentation and New Product Development" in the recent update to The PDMA Handbook of New Product Development. In addition, Mr. Bonifant has written case studies on the pharmaceutical industry used in graduate business programs. He has been a guest lecturer at the Fuqua School of Business, the Indiana University Kelly School of Business, and many industry conferences in the US and Europe. Mr. Bonifant earned an M.B.A. from the Stanford Graduate School of Business and a B.S. in mechanical engineering from Duke University.

[back to top]

Daniel Broderick
Daniel Broderick is the Associate Director for the California Institute of Technology Office of Technology Transfer. He is responsible for business matters ranging from negotiating license agreements, managing patent prosecution, and forming new startups. Dan began his technology transfer career at Northwestern University, and went on to assist with the start-up of the Technology Transfer Office at the University of California San Diego as its first licensing associate. He then joined Wesley Jessen Vision Care as the Director of Business Development in 1997, where he identified acquisition targets and strategic partners, managed business alliances, directed the prosecution of a large intellectual property portfolio, and negotiated a wide range of business agreements. After Wesley Jessen was purchased by Novartis, Dan became the Director of Business Development at Apovia Inc. , a biotechnology company in San Diego, CA that developed recombinant vaccines. From 2004 to 2008, Dan was the Director of the College of Engineering Office of Technology Transfer and Commercialization at the University of Michigan. Dan received his Bachelor of Engineering degree at the University of Michigan, his Master of Science in Electrical Engineering from Northwestern University, and his MBA from the University of Chicago. He has been patent agent since 1995.

[back to top]

Jim Burger
Jim Burger is a member of Dow Lohnes specializing in the representation of technology companies on intellectual property, communications, and government policy matters. Jim joined the firm's Media, Information and Technologies group in January, 1997. Before Dow Lohnes, Jim was a Senior Director in Apple Computer's Law Department. Jim has worked extensively on legal and policy issues arising from the confluence of digital technology, communications, IP protection and government regulation, particularly as affecting digital content, DTV, wireless data, and the Internet. He currently serves as the Co-Chair of FCBA's Intellectual Property Committee. Jim was named in the 2007, 2008 and 2009 Washington Post, The Best Lawyers in America in the specialty of Technology Law. Jim received his Bachelors (with Honors) and Masters from New York University and his Law (cum laude) degrees from New York University School of Law, where he served as an editor of the NYU Law Journal.

[back to top]

James Burns
James S. Burns is President, CEO and a director of AssureRx Health, a personalized medicine company providing clinically-relevant information to help physicians select the right medication and dose for behavioral health patients. Mr. Burns has over 30 years executive experience in the pharmaceutical, biotechnology, medical device, and diagnostic fields. He has served in leadership roles ranging from commercialization, financial, business development, and general management within businesses ranging from early-stage companies to large multinational corporations, venture capital, and private equity. He has served as President and CEO of EntreMed; as President and EVP of MedPointe Pharmaceuticals; Managing Director and founder of MedPointe Capital; President, CEO and a founder of Osiris Therapeutics; a founding General Partner of HealthCare Ventures LP; Group President at Becton Dickinson; and a Partner at Booz Allen Hamilton. He is a director of Vermillion and Symmetry Medical.

[back to top]

Angela Bylancik
Angela Bylancik CLP, CA-AM joined the pharmaceutical industry in 1984 as a sales representative for Hoffmann-LaRoche.   She worked for Roche for 17 years holding positions in Market Research, in-line Marketing, and New Product Planning in such diverse therapeutic areas as CNS, Dermatology, Oncology, Virology, and Metabolic Disease.  In 2001 Ms. Bylancik joined Novartis as the Product Director for Foradil and took on the role of Alliance Manager when the product was licensed to Schering in 2002.  Since joining Novartis she has worked in New Product Commercialization, US BD&L Negotiation and Alliance Management, and most recently as Global Alliance Manager in the Integrated Hospital Care Franchise.  Ms. Bylancik has a B.S. in Economics from the University of Wisconsin.

[back to top]

Lisa Cameron
Dr. Lisa Cameron, a Senior Consultant at The Brattle Group, has spent most of her consulting career on intellectual property issues and matters involving the energy industry.   In her intellectual property work, she has prepared testimony on irreparable harm and commercial success on behalf of both plaintiffs and defendants.  She has also prepared testimony on reasonable royalties and lost profits for clients in industries ranging from software to consumer products to pharmaceuticals and medical devices.   In her energy industry work, Dr. Cameron has served as both a consultant and an expert on numerous cases.  She has also published a number of papers on energy industry topics in leading academic and professional journals. Prior to becoming a consultant, Dr. Cameron was an assistant professor in the Graduate School of Business at Carnegie Mellon University.  Dr. Cameron received her Ph.D. in Economics from Stanford University and her B.Sc. in Applied Economics from Cornell University.

[back to top]

Susan A. Capello
Susan A. Capello is a Senior Intellectual Property Attorney for Intel Corporation. She graduated from West Chester University of Pennsylvania with a Bachelor of Science in Chemistry/Biology and Business Administration and worked in scientific research capacities with Hoffman-LaRoche, Inc. and the Rorer Group, Inc. . Ms. Capello received her Juris Doctor from Pace University School of Law in 1989 and spent several years in private practice before becoming an in-house IP attorney. As in-house counsel she has worked for Becton, Dickinson and Company; Lipid Sciences, Inc. and Connetics Corporation.

[back to top]

Frederick Cartwright
Fred has spent 30 years in the automotive industry with General Motors.  This has included the design and development of advanced powertrains for commercial/military vehicles, management of GM's hybrid bus program, and multiple facets of new business development and collaboration.  He has served as the Director of Technology Planning for GM Powertrain and, for the last three (3) years, the Director of New Business Development for General Motors Company.  In this role, Fred has had responsibility for the development of an IP strategy for GM, the negotiation and execution of multiple complex deals involving new technology, as well as overall responsibility for management of GM's deal pipeline. He has a BS in Mechanical Engineering from Rose-Hulman Institute of Technology and an MBA from Butler University.  

[back to top]

Daniel Castro
Daniel Castro is a Business Strategy and Licensing Manager in the office of Research Ventures and Licensing at Partners Healthcare System/Massachusetts General Hospital ("MGH").  In this position, Dan manages the licensing of intellectual property developed in MGH's Department of Anesthesia, Center of Systems Biology, Center for Molecular Imaging and the Center for Computational and Integrative Biology.    Prior to joining Partners Healthcare, Dan was the Associate Director for the Program and Portfolio Management group at Antigenics, where his responsibilities included managing drug development project teams and prioritizing the clinical drug development pipeline.  Formerly, Dan worked in the Portfolio Management group at Sanofi-Aventis, where his responsibilities included the prioritization and optimization of the drug development pipeline.  Dan holds an MBA from Boston College, and is a registered patent agent.

[back to top]

Cheryl Cejka
For the past ten years, Cheryl Cejka has led PNNL's intellectual property management, portfolio development and investment, and technology commercialization activities. She has held a broad range of business management and technology development positions with PNNL (a $1B DOE national lab) and for Battelle, which operates PNNL and 5 other DOE national laboratories for the U.S. Department of Energy. Her areas of expertise include finance, contracts, business and technology development, licensing, and commercialization.

Since becoming director, Cheryl has dramatically increased PNNL's annual returns from intellectual assets. She has led the creation of many significant technology licensing arrangements, including the establishment of several new business ventures based on Battelle-owned and laboratory developed technologies. Many of these transactions have received national recognition from the Federal Laboratory Consortium for Excellence in Technology Transfer. PNNL is recognized as a leader in commercialization "best practices" across the DOE and 300+ federal lab system.

Cheryl has been recognized for her achievements in the areas of new business development, organizational redesign, licensing, and commercialization. She has contributed significantly to many Battelle proposals for new contract opportunities, including leading the Economic Development and Technology Transfer component of Battelle's successful $5 billion bid to operate Oak Ridge National Laboratory for DOE.

Cheryl received a bachelor's degree in business and marketing and an MBA in finance, both from the University of Washington. She is an active member of the Licensing Executives Society, the Industrial Research Institute and the Association of University Technology Managers, and is a Fellow in the National Contracts Management Association.

She is the immediate past chair of the National Technology Transfer Working Group's executive committee, which is composed of appointed technology transfer leaders across the DOE national lab system. Cheryl serves on the executive board as Member-At-Large for the Federal Laboratory Consortium, a nationwide network of more than 700 federal laboratories that provides a forum for developing strategies and leveraging opportunities to link laboratory innovations with the market. She is also chair-elect of the Industry-University-Government Interface (IUGI) sector, one of five sectors in the USA/Canada chapter of the Licensing Executives Society (LES). Cheryl also serves on the Washington Economic Development Commission steering committee for technology commercialization, the Battelle Commercialization Council, the advisory board for Washington State University's Center for Entrepreneurial Studies, and the commercialization advisory council for the Oregon Nanoscience and Microtechnologies Institute. She leads the Industrial Research Institute's Committee on Managing Technology Transfer and is an active contributor to the National Association of Seed and Venture Funds.

Outside of her professional activities, Cheryl is an Executive Volunteer with the Mid-Columbia Chapter of the American Diabetes Association.

[back to top]

Hector Chagoya
Hector Chagoya, Partner and Director of IP Value Extraction at Becerril Coca & Becerril. With an IP experience since 1997, he holds the Certified Licensing Professional credential (first in Mexico) and has been recognized as a leading patent practitioner. Currently in charge of consulting services for leveraging value from IP assets, he focuses his practice in leading working teams through technology intelligence studies, IP assets valuation, IP negotiations, technology evaluation and substantive issues of patent litigation.

[back to top]

Guy Chambers
Guy W. Chambers is a partner in Duane Morris' San Francisco office.  Mr. Chambers' practice includes litigation in court of patent matters, biotechnology interferences, technology licensing and patent prosecution.  He has been lead counsel in more than 40 intellectual property lawsuits and Patent Office interferences.  For 15 years, Mr. Chambers was the project manager on a patent services contract with the National Institutes of Health.  During this time, Mr. Chambers worked extensively with the NIH on patent protection issues concerning the NIH's HIV patent portfolio.  Mr. Chambers regularly teaches advanced patent licensing for the Practising Law Institute.

[back to top]

Linda Chao
Linda Chao is a senior licensing associate in Stanford University's Office of Technology Licensing (OTL).  At OTL, Linda manages an intellectual property portfolio of over 300 inventions, including nanotechnology, photonic, semiconductor, and bioengineering technologies, and negotiates licenses with companies ranging from start-up ventures to Fortune 500 companies.    Linda is also an active member of the Licensing Executives Society (LES), including chair of the LES Foundation Graduate Student Business Plan Competition, co-chair of the LES International Education Committee, and LES Silicon Valley Chapter Education Chair.    Her technical and business experience includes microprocessor design at Digital Equipment Corporation, industry analysis at SEMATECH, and product marketing at Applied Materials.  She is a registered USPTO patent agent and a Certified Licensing Professional.  Linda received a BSEE, a MSEE, and a MS in Management from Massachusetts Institute of Technology.

[back to top]

Elizabeth Chien-Hale
Elizabeth Chien-Hale is a registered U.S. patent attorney specializing in patent and other forms of intellectual property protection. She is bilingual in Chinese and English, and concentrate on patent issues in both the United States and China.

Prior to consulting, she headed the patent practice at Baker & McKenzie's Hong Kong office. She also worked for other law firms in Silicon Valley including Wilson Sonsini Goodrich & Rosati, and Fish & Richardson. She was also a visiting attorney at several foreign law firms over the years.

Ms. Chien-Hale has substantial technical knowledge in a variety of electrical and electro-mechanical arts, having drafted and prosecuted patent applications in telecommunication, software, wireless and Internet-enabled devices, language-based data processing, semiconductor processing and computer-related mechanical devices. She was also involved in a number of intellectual property litigation cases, including cases in the International Trade Commission and the U.S. District Court, relating to patent infringements and trade secrets violation.

Ms. Chien-Hale has lectured and written, in both English and Chinese, on the topics of international intellectual property protection and the Chinese constitutional structure. She was a research scholar at the College of law of the Peking University and taught at the graduate school of the Chinese Academy of Social Sciences in 1995. She is a registered patent attorney before the U.S. Patent and Trademark Office, and is licensed to practice in the states of California, Hawaii, and the District of Columbia. She is also admitted to the Bar of the U.S. Supreme Court. Her name has been included in the Who's Who in America, Who's Who in American Law, and Who's Who in American Women.

Ms. Chien-Hale is also an active participant in the professional organizations. For the American Bar Association, she currently co-chairs the Committee on International Patent Treaties and Laws for the Intellectual Property Law Section, and co-chairs the Joint Task Force between the Intellectual Property Law Section and the International Law Section on PRC Intellectual Property Laws Amendments. She is also a co-chair of the Intellectual Property Law Interest Group and the vice-chair of the Pacific Rim Interest Group of the American Society of International Law.

[back to top]

Kimberly S. Chotkowski, Esq.
Ms. Chotkowski earned her Bachelors degree in Electrical Engineering from Worcester Polytechnic Institute, Worcester, MA in 1993 her Juris Doctor from the Franklin Pierce Law Center in 1996 and a MBA in Finance from Sacred Heart University, Fairfield, CT in 2000. In 2006, she joined ATLC, Inc. (ATLC) specializing in assisting clients to maximize their financial return on Research and Development through licensing of their patented technology. Kim provides a value added and proven service by successfully increasing licensing revenues while also shortening the timetable in achieving such revenues. Kim supports a broad range of technologies and works either independently or with in-house licensing programs. Kim understands and has significant global licensing experience that compliments Andre-Troner's first class 5 person team which has negotiated with about 70 companies worldwide and obtained licenses worth almost $2 billion on behalf of their clients. Kim has led Andre-Troner to become involved with significant patent brokerage agreements and has helped expand its client opportunity.

Kim started her career in law with Hopgood, Calimafde, Kalil and Judlowe in New York City (now merged with Morgan and Lewis) practicing in their patent litigation group. She later moved to Pitney Bowes, Inc. of Stamford, CT as Senior Patent Attorney where she was a member of their Capital Asset Management team in which she was responsible for Corporate IP licensing activities.  In 2001, Kim became employed with InterDigital Communications Corporation where she was Senior Director, Intellectual Property Licensing Strategy and Litigation.  She was also appointed Vice President Patent Portfolio Management for ITC, InterDigital's Patent Holding Company. Kim was a member of the global licensing team contributing to over 400 million dollars of licensing revenue for the Company. Some of the noteworthy deals include a License to LG Electronics, Kyocera, Toshiba, Panasonic, Lucent Technologies, HTC and many others totaling several hundred million US dollars.

Also, during her tenure at InterDigital Kim was responsible for strategically growing the Patent portfolio resulting in portfolio expansion of over 500% to help ensure InterDigital's licensing success for many years. Kim has been a frequent speaker for the Licensing Executive Society speaking at certain of the Annual, Spring, and International Meetings. She has also spoken on behalf of the US State Department on Licensing in China. She has written a chapter for Practical Engineering Design, Intellectual Property published by CRC Press, 2005 used by Boston University Engineering Students. She has also been published in The International Lawyer, Les Novelles, and The Computer Lawyer on Financial Considerations in International Intellectual Property Licensing Transactions.

[back to top]

Brad Close
Brad Close is a graduate of Franklin Pierce Law Center, with a JD and Masters of Intellectual Property.  He has practiced in the areas of patent prosecution, licensing, contracts and brokering.  Brad has managed portfolio transfers for large multinational companies as well as small individual inventors.  He specializes in seller-side brokering.

[back to top]

Jason Cole
Jason Cole, Esq. is an experienced transactional biotechnology lawyer and business advisor. Mr. Cole has served as Senior Vice President, General Counsel and Secretary of Zalicus' predecessor CombinatoRx, a Nasdaq-listed biotechnolgy company, since January 2006.  Mr. Cole has responsibility for consummating financing transactions; negotiating and documenting business development transactions; negotiating and completing merger an dacquisition transactions, overseeing the legal aspects of clinical development, manufacturing and research; and managing the company's extensive IP portfolio.  From 1999 to 2006, Mr. Cole was a corporate and securities attorney at Ropes & Gray LLP, with a focus in the life sciences. Mr. Cole holds an A.B. in Government from Dartmouth College and a J.D. from Columbia University School of Law.  

[back to top]

Lynda Covello
Lynda Covello, LL.B., LL.M. is a multilingual international lawyer, IP strategist and business consultant with over 23 years experience in the strategic use of intellectual property assets in business, particularly healthcare, IT and biotech. She advises on IP-related business strategies, technology transfer, licensing, commercialization, monetization, international expansion and IP-related transactions globally. She is experienced in conflict resolution, relationship management and negotiation. Ms Covello has advanced problem-solving skills. Ms. Covello has served as both an external advisor to business and a member of the executive management team, giving her a practical and realistic perspective on the key issues and concerns facing business decision-makers. Ms Covello is C.E.O of LPC Consulting International, based in Toronto, Canada, with a worldwide network of contributing consultants.

[back to top]

Hal Craig
Hal Craig founded Trout Creek Consulting on the principle that management consultants with strong problem solving and finance skills, significant operating experience, and industry knowledge will deliver superior value to clients. TCC creates value for clients by providing Actionable Strategies, Objective Valuations, Scenario Planning, Supply Chain Creation & Optimization, Development Portfolio Optimization, and Corporate Development. Mr. Craig's experience includes general management, international M&A, manufacturing, product development, and strategic planning. He has provided assessments on >300 M&A, licensing, JV, internal growth, and VC opportunities across the CEEM and Life Sciences sectors. Mr. Craig, who earned his MBA from the University of Michigan and his BSChE from the University of California at Berkeley, is on the Investment Advisory Committee of Ben Franklin Technology Partners.

[back to top]

Anthony del Campo
Mr. del Campo has been VP, Research and Technology Ventures (ORTV) at the Dana-Farber Cancer Institute since 2002.  At ORTV, he oversees the technology transfer efforts of the Institute.  Previous to ORTV, he has held senior corporate development positions in industry, including Genome Therapeutics Corporation where he was responsible for business transactions including product in-licensing and strategic partnerships.  Previously, he was the Director of Business Development at BCM Technologies, Inc., of Baylor College of Medicine and was a Licensing Specialist at the M.D. Anderson Cancer Center.  Prior to his business development career, Tony held research scientist positions at the LifeCell Corporation and at the National Cancer Institute.  He holds an undergraduate degree in Biology from the University of Maryland Baltimore County and attended graduate school at Georgetown University.  He also holds an MBA from the University of Houston and is a Certified Licensing Professional (CLP)

[back to top]

Patrick Desmond
Patrick Desmond is USG Corporation's manager of technical licensing and has been with USG for over 25 years in various business, legal, technical and manufacturing positions. He holds two undergraduate technical degrees and an MBA. He also earned his Juris Doctorate graduating at the top of his class from the University of Toledo and is a member of the state bars of Ohio, Michigan and Illinois. His duties span legal and business functions, including global intellectual property management, drafting and negotiating of licensing agreements, technical transfer oversight, and technology valuation.

[back to top]

Lisa Dhar
Lisa Dhar is a Senior Technology Manager at the Office of Technology Management at the University of Illinois, Urbana-Champaign.  Previously, she was vice president of media development at InPhase Technologies, a company she co-founded with colleagues from Bell Laboratories, Lucent Technologies.  Lisa has served on the National Academies' Assessment Panel on Materials Science and Engineering at the National Institute of Standards and Technology (NIST) and on the Advisory Board for University of Colorado's Women in Engineering. Lisa holds a Ph.D. in Physical Chemistry from the Massachusetts Institute of Technology and a Bachelor's Degree in Chemistry from the University of Chicago. 

[back to top]

Amit Dhawan
Amit Dhawan, M.D., M.B.A., M.H.A., is the Medical Director at Kantar Health. Dr. Dhawan has expertise in clinical medicine, new product analysis, epidemiology, and market trend forecasting. Dr. Dhawan holds an M.D. and an M.B.A. from the University of Missouri-Kansas City, and an M.H.A. from the Washington University School of Medicine.

[back to top]

Roberto Dini
With more than 35 year experience, Mr. Roberto Dini is one of the best known and appreciated experts in the field of Intellectual Property. He began his career in the Intellectual Property field with Indesit. In Indesit he's been Head of the Patent and Trademark Office. In 1982, Mr. Dini founded Sisvel, which has soon become a world leader in managing IP and maximizing the value of patents. With Sisvel he has developed an invaluable experience in arranging and managing patent pools. Mr Dini has extensive expertise in filing and prosecuting patents, designs and trademarks; drafting contracts for the purchase or license of patents; negotiations with multi-national companies. Mr Dini is presently the CEO of Metroconsult, an Industrial and Intellectual Property Consultancy Firm based in Turin, with branch offices in Milan and Genoa.

[back to top]

Don Drinkwater
Mr. Drinkwater currently directs the licensing group for a major consumer electronics company.

Mr. Drinkwater has contributed to the Consumer, Computer and Networking industry for over twenty years. He has held principal engineering and senior management level positions including group manager of Digital Equipment Corporation's and Compaq Computer Corporation's Corporate Licensing Office. Don worked with clients to improve intellectual asset utilization while at Standard and Poors and PricewaterhouseCoopers and served as director of licensing for 3Com Corporation.

Mr. Drinkwater has a Bachelor of Science Degree in Electrical Engineering from the University of Massachusetts at Lowell, a Master of Science Degree in Electrical Engineering from Worcester Polytechnic Institute, and a Master of Business Administration from Clark University. Don is a member of Eta Kappa Nu (the honor society of the Institute of Electronic and Electrical Engineers ("IEEE") and won the Haskell Memorial Award for distinguished teaching at the University of Massachusetts at Lowell. Mr. Drinkwater holds seven patents.

Mr. Drinkwater has published articles in les Nouvelles (the Journal of the Licensing Executive Society, "LES") and IEEE publications. He is a member of the IEEE, LES, and spent fifteen years serving as an adjunct faculty member at the University of Massachusetts at Lowell.

[back to top]

Ben du Pont
Ben is co-founder and President of yet2.com, a global marketplace for technology. Founded in 1999, Yet2.com creates mutually beneficial partnerships between companies leveraging new technology and patents. yet2.com was one the worlds first Open innovation platforms. 1/4 of the Fortune 500 directly engage yet2.com and most of the Fortune 500 are engaged in deal disucssions through yet2.com, in deals ranging from new drug delivery technologys to new heavy oil recovery technologies..

yet2.com has offices in; Boston, Liverpool, Tokyo and Wilmington Delaware. It was jointly funded by; Siemens, Bayer, Caterpillar, Honeywell, P&G, DuPont and NTT Leasing.

Prior to founding yet2.com, he spent 14 years with DuPont in a variety of leadership positions in; Specialty Chemicals, Fibers and Automotive business units. Ben has a 1986 BSME from Tufts University and is a director of; Morgan Stanley Capital Index NYSE:MXB, Vianix (a speech compression company), Platinum Research, Longwood Gardens, Jefferson Awards (the highest award for public service in the US) and the Tower Hill School. Ben is a licensed pilot, a ham radio operator and an avid sailor. Ben lives with his wife, Laura and 2 children in Wilmington Delaware.

[back to top]

Halina Dziewit
Halina S. Dziewit, Partner, Patton Boggs LLP Halina Dziewit has over 25 years of Intellectual Property law experience. Ms. Dziewit represents high-technology clients, both U.S. and foreign, in a variety of areas, including computer hardware, software, biomedical instrumentation, energy, and atmospheric and climate instrumentation. Ms. Dziewit primarily focuses on licensing and technology transactions in the private commercial sector, the non-profit sector, academic sector and U.S. and foreign government sector. Ms. Dziewit has worked with numerous start-ups and has significant experience with Technology Transfer. 

[back to top]

Mark Edwards
Mark G. Edwards is Managing Director of Deloitte Recap LLC, a wholly-owned subsidiary of Deloitte Touche Tohmatsu.  Until its sale to Deloitte in 2008, Mr. Edwards was the Managing Director and founder of Recombinant Capital, Inc. (Recap), a consulting firm based in Walnut Creek, California. More than 600 biotechnology, pharmaceutical and service companies subscribe to Recap's databases or have retained Recap to advise on biotech alliances and valuations.  He has provided expert testimony in lawsuits involving reasonable royalties, transfer pricing and custom and practice for contracts in the biotechnology and pharmaceutical industries.  Prior to founding Recap in 1988, Mr. Edwards was Manager of Business Development at Chiron Corporation. He received his B.A. and M.B.A. degrees from Stanford.  

[back to top]

Linda Egger
Linda Egger earned a BS in biology from Cook College, Rutgers University, an MS in physiology/neurobiology from Rutgers Graduate School, and a PhD in cell and developmental biology from the UMDNJ/Rutgers Graduate School. Prior to joining Merck, Linda worked at BioMetallics Inc. as a biochemist and at Wyeth-Ayerst Research as a pharmacologist. Linda joined Merck Research Laboratories in 1990. Over the next 14 years, Linda carried out basic research in the Immunology and Pharmacology departments. Linda joined External Scientific Affairs in 2004 as a senior scientist, Scientific Licensing, where she identified and evaluated external research and licensing opportunities in the therapeutic areas of diabetes, obesity, atherosclerosis, and cardiovascular disease. Linda is currently a Senior Director, franchise licensing integrator at Merck.  

[back to top]

William Elkington
Bill is Senior Director, Strategic Technology, at Rockwell Collins.  He is responsible for protection, value extraction, and rights management strategies concerning Rockwell Collins's strategic intellectual property.  His group works with the company's business units to value IP and to structure both upstream and downstream licenses in the normal course of its business.  He is also responsible for licensing Rockwell Collins's technology into markets it does not serve.  Prior to joining Rockwell Collins, Bill was co-founder and VP of Program Management at MeshNetworks, a wireless company established to commercialize ITT's wireless technology.  MeshNetworks was sold to Motorola in 2004.  Prior to joining MeshNetworks, Bill held positions in licensing, technology marketing, and program management in ITT's Aerospace/Communications Division (A/CD) and GE R&D organizations.  Bill is a Phi Beta Kappa graduate of the University of Michigan, with advanced degrees from Syracuse University.

[back to top]

Steven M. Ferguson
Steven M. Ferguson currently serves as the Deputy Director, Licensing and Entrepreneurship. Prior to joining NIH Office of Technology Transfer in 1990, Mr. Ferguson served in marketing and management positions in biomedical firms subsequent to being a scientist at the National Cancer Institute. His healthcare experience has also included work as Director of Marketing and Public Relations for a rural 70-bed hospital. Registered to practice before the USPTO, Mr. Ferguson also holds Master's Degrees in Business Administration (George Washington University) and Chemistry (University of Cincinnati) as well as Bachelor's Degree in Chemistry (Case Western Reserve University).

Mr. Ferguson has been an economic reviewer for Maryland Industrial Partnerships (MIPS) as well as the Advanced Technology Program (ATP) grant programs and is an instructor for both the USDA Graduate School and the NIH FAES Graduate School where he is also the department chair for the new Certificate in Technology Transfer Program. Mr. Ferguson was also the Susan T. and Charles E. Harris Visiting Lecturer at the Watson School of Biological Sciences at the Cold Spring Harbor Laboratory and has published articles on licensing and technology transfer issues.

[back to top]

Allison Formal
Ms. Formal, joined the Research Department of the Leukemia & Lymphoma Society as Vice President, Research Business Development.    Allison has over twenty years of experience in business development, contracting, and project management in the pharmaceutical and biotechnology industries.  Her previous positions include Vice President, Business Development, MediQuest Therapeutics, Vice President, Business Development, Neuralstem, Director, International Division, Watson Pharmaceutical.  Allison started her career with Pfizer as a professional sales representative in the 1980s.

At LLS Allison is responsible for helping to identify and vet biotechnology and pharmaceutical company opportunities that come through the Therapy Acceleration Program (TAP), the negotiation and execution of contracts with industry partners and together with the TAP team, the post-contract project management of those partnerships.  Allison also assumed responsibility for managing the LLS Intellectual Property portfolio.

Allison received her MBA from Marymount University and her undergraduate degree from the American University in Washington D.C.

[back to top]

Lauren Foster
Lauren C. Foster is Assistant Director, Biotechnology of M.I.T.'s Technology Licensing Office (TLO). Prior to joining M.I.T., Lauren was Senior Director, IP and Technology Acquisition at Antigenics, Inc., a public biotechnology company, where she played an integral role in envisioning and implementing the company's business, intellectual property and technology strategies. Lauren was also a Technical Specialist at the law firm Lahive & Cockfield LLP where she focused on strategic development of intellectual property rights for biotechnology and pharmaceutical companies and universities. Ms. Foster holds a D.Sc. from Harvard University and a B.S. from Haverford College, and is a registered Patent Agent.

[back to top]

David Fraser
David Fraser has over 20 years experience in the fields of intellectual property and electronic engineering. Prior to joining GIS, David was a Principal at Semiconductor Insights working in licensing strategies and patent claim applications with a particular emphasis on semiconductor devices and computer systems. He also provided patent portfolio analysis and evaluation services. Previously, David spent 15 years in various technical positions in Canada and Japan where he worked on designing electro-optical systems for the telecommunications industry as well as conducting research in parallel computing, computer architecture, ATM and SONET network systems. David has published articles in the EE Times and presented at LES meetings.

David Fraser holds a M.A.Sc in Electrical Engineering from the University of British Columbia and a B.Sc.Eng. in Mathematics and Engineering from Queen's University, Kingston, ON. David has published articles in the EE Times.

David is a Member of the Licensing Executives Society (USA & Canada), Inc.; and the Professional Engineers of Ontario.

[back to top]

Dr. Christine T. Fischette
Dr. Christine T. Fischette has held this position since January 2008. Before her employment with Enzo, she was Executive Director and Head of Negotiation, Global Business Development and Licensing for various therapeutic Business Franchise Boards at Novartis Pharmaceuticals from 1999-2007. She held various positions of increasing responsibility at Pfizer Pharmaceuticals, NY and directed preclinical/clinical development, IND's/NDA's, medical marketing, and was head of Pfizer's US commercial arm for diabetes before joining Business Development and Licensing from 1987-1999. Prior to her work experience at Pfizer, she conducted research as Senior Scientist at Hoffmann-La Roche, Inc. and as a Post-Doctoral Fellow/Research Associate at Rockefeller University, NY. Dr. Fischette holds a Ph.D. in Physiology from the University of Medicine & Dentistry of New J She has authored over 50 publications in peer-reviewed publications, including Science.

[back to top]

Brian Frizzell
Mr. Frizzell is a Principal in the IP practice at Charles River Associates.  His experience includes valuation of patents, trade secrets, trademarks, software, and ongoing and startup businesses both inside and outside the context of litigation.  Mr. Frizzell's experience spans across multiple industries, including software, telecommunications, consumer products, medical devices, financial markets, energy, utilities, and media.  He has valued large patent portfolios as part of bankruptcy proceedings, evaluated appropriate lost profits and reasonable royalty patent damages stemming from patent disputes, examined IP landscapes in the context of making strategic business decisions, and valued individual patents for sale or donation.  Mr. Frizzell is a Chartered Financial Analyst ('CFA'), a Certified Fraud Examiner ('CFE').  He earned his BSEE from the University of Illinois and his MBA with distinction from Northwestern's Kellogg Graduate School of Management.  

[back to top]

Paul Gallagher
Paul Gallagher, President of Compass Strategic Consulting, founded the company in 1994, after 16 years on the big pharma side, starting in product management and navigating through two companies to VP of Global Marketing for Ayerst (Wyeth). In its fifteen years, Compass has moved from specializing in a full range of business development services in the life sciences to one predominantly focused on global market access intelligence and strategies. Compass provides pricing and reimbursement assessments and strategies primarily for pipeline products, in the pharma, biotech, and diagnostic sectors. Clients include biopharma companies, from emerging to top ten, and venture funds. Compass is located in New Haven, CT where it benefits from access to resources and talent of Yale University. Paul holds a BA in economics from Columbia University and an MBA in marketing from George Washington University. He is Co-Chair of the CT Chapter of LES.

[back to top]

Patrick G. Gattari
Patrick G. Gattari's practice includes patent procurement, technology transactions, and client counseling in relation to patent enforcement with emphasis in the chemical, pharmaceutical, diagnostic, and biotechnology arts. His practice focuses on counseling clients with respect to patent portfolio procurement and management, and the development, licensing, acquisition, and sale of intellectual property and technology. His work includes the structuring and negotiation of technology related transactions including collaboration, joint development, consulting and outsourcing agreements, and technology assignments and licenses. He also counsels clients on the intellectual property components of mergers, acquisitions, and venture capital related transactions.  Prior to joining MBHB, Mr. Gattari was patent counsel at Dade Behring, Inc. (now Siemens Healthcare Diagnostics), where his work emphasized patent prosecution and technology transactions.

[back to top]

Paul Germeraad
President of Intellectual Assets, Inc., a professional advisory services firm specializing in integrated business, R&D, and IP processes.  Intellectual Assets, Inc. is distinguished by using cutting edge IP assessment tools and proprietary software, in addition to offering invaluable insight based on the depth and breadth of executive level management experience and industry coverage the firm's members represent.

Dr. Germeraad was previously Chief Operating Officer for Aurigin Systems, Inc., a software start-up company, where he focused on the development of the company's intellectual asset management products for the Competitive Intelligence, Licensing and R&D communities. Prior to joining Aurigin in 1998, Paul worked for three Fortune 500 companies.  He served as Vice President, Corporate Research for Avery Dennison, as the executive responsible for the Corporate Research Center. Before joining Avery Dennison, Paul was director of James River Corporation's Flexible Packaging Technical Center and held a variety of R&D and management positions at Raychem Corporation.

Paul is past Chairman of the Industrial Research Institute, an organization of Chief Technology Officers whose organizations account for over 70% of all US R&D spending.  Paul joined the Licensing Executives Society (LES) Board of Trustees in 2002, served as Vice President, Education in 2004, and is chair of the LESI Long Range Planning Committee.  He is an instructor for the LES Professional Development Series.

Paul is a graduate of the University of California, San Diego, with a B.A. in Chemistry. In addition, Paul holds a Ph.D. in Chemistry from the University of California, Irvine and an LL.B degree from La Salle Extension University.  He has also received the CLP designation from LES USA-Canada.

[back to top]

Adam Golden
Adam Golden is a Partner and Co-Chair of the Corporate & Finance Department of Kaye Scholer LLP. He also heads the firm's Life Sciences Transactions group. His practice focuses on structuring and negotiating complex business transactions, including mergers and acquisitions, joint ventures, and the full range of licensing and collaboration transactions common to the life sciences sector. He has represented issuers and investors in public and private securities offerings, including venture capital, private equity and PIPE financings. His practice is international in scope, and his clients range in size from multibillion-dollar global businesses to emerging-stage companies. Chambers USA: America's Leading Lawyers for Business (2009 and 2010) recognized Mr. Golden and rated Kaye Scholer's multidisciplinary Life Sciences practice as being among the strongest in the nation, winning praise for "comprehensive service" with a "results-oriented approach and deep understanding of the market.

[back to top]

Michael Graham
For more than 20 years, Michael R. Graham has counseled and represented clients in the areas of trademark, copyright, licensing, and internet-related law.  A graduate of Miami University, he holds a Masters Degree in English from Ohio University and a J.D. from Fordham School of Law.  Prior to entering the law, he worked for seven years in trade publishing and arts administration.  He was one of the first attorneys to recognize and assist clients in commercializing and protecting trademarks and copyrighted materials on the Internet.  Awarded a Martindale-Hubbell® AV Peer Review Rating™ and as a Leading Lawyer of 2009 and 2010, Mr. Graham helps clients establish programs and strategies to establish and protect core business assets, and ensure and enforce their  rights. He also provides counseling and assistance to artitists, writers, and musicians and provides pro bono assistance through Lawyers for he Creative Arts.  

[back to top]

Paul V. Greco
Paul V. Greco is Vice President of ICAP Ocean Tomo, an intellectual property brokerage firm based in Chicago, IL.

Prior to his affiliation with ICAP Ocean Tomo, Mr. Greco was a Director at Ocean Tomo and was engaged in the private practice of law for 19 years, focusing on corporate finance, M&A, securities and intellectual property matters for businesses in the on-line, software development and consumer products industries. In 2004 he founded and partnered in Sierchio Greco & Greco, LLP, a boutique securities law and venture capital practice. From 2001 through 2004 he was a principal in the law firm of Garvey Schubert Barer, a multi-jurisdictional, full-service firm. Prior to this he co-founded and was a principal partner in Aieta & Greco, a securities, IP and venture capital boutique located in the hub of New York's Silicon Alley.

Since 1999, Mr. Greco has been Director of AGB2 Inc., a privately held intellectual property development and holding company. He is also currently a Director of PolyOptic Technolgies, Inc., a privately held optical switch design and consulting firm based in Wisconsin. He is also a member of the Executive Board of the Westchester-Putnam Council of the Boy Scouts of America, Inc. and is listed as an inventor on two issued U.S. patents.

Mr. Greco graduated cum laude with a B.A. in English from Boston College and received a J.D. from Fordham University School of Law. He is admitted to the New York, SDNY and EDNY bars.

[back to top]

Richard Greeley
Richard Greeley is a Director in the IP Licensing Group at Microsoft. Previously, he worked at Digital Equipment Corporation, Compaq and HP in a variety of licensing, business development, product management,  strategy, engineering and training positions.

[back to top]

Kamal Hassin
Kamal is responsible for current and future product portfolio capabilities in Protecode. Kamal is the author or co-author of a number of papers on Software Intellectual Property management. His strong technology background coupled with close knowledge of Intellectual Property issues in the software industry has propelled Protecode to its dominant position of in a short period of time. Kamal has a Bachelor of Engineering degree and a Masters degree in Technology Innovation Management from Carleton University.

[back to top]

Jaime Heins
Jaime Heins is Associate General Counsel for Burton Snowboards, a Burlington, Vermont-based snowboard company solely dedicated to creating and perfecting a full range of the best snowboarding equipment and apparel.  Privately held and headquartered in Burlington, Vermont with international offices in Innsbruck, Tokyo and Sydney, Burton is the world's leading snowboard company and owns other top board sports brands, including Channel Islands Surfboards, Habitat Skateboards, Analog Clothing, Gravis Footwear, anon Optics and R.E.D. Protection. Mr. Heins manages transactional legal matters for Burton and its global family of brands, including drafting, review and negotiation of professional athlete, sponsorship, manufacturing and related commercial agreements. Mr. Heins also provides counsel to Burton with respect to mergers and acquisitions, intellectual property, employment and litigation matters. Mr. Heins received his J.D. from the University of  Pennsylvania Law School.  

[back to top]

Elias Hinckley
Elias Hinckley advises clients in the clean and renewable energy industries on business, policy, tax and regulatory issues.  He has worked on diverse matters ranging from the operations of energy markets to individual project finance, including tax, carbon and REC financing, to integration of renewables with regulated utilities.  He has been a lead advisor on several clean energy projects, including wind, solar, biomass, geothermal, fuel cells, and hydroelectric.     Elias is a professor of international energy policy at Georgetown University and regularly acts as a strategic advisor on both energy markets and the evolving energy policy landscape.  He also is a frequent speaker on energy matters.  Elias joined Venable from Deloitte & Touche LLP, where he was the U.S. Practice Leader for the Alternative Energy Tax practice, was co-architect of Deloitte's global strategy on climate change and a leader of the firm's sustainability practice.  

[back to top]

Yorikatsu Hohokabe
Dr. Yorikatsu Hohokabe joined Oblon, Spivak as a Senior Technical Advisor.  Before joining the firm, he worked for Showa Denko K.K. (Japan) for 36 years, serving in several management positions including Senior Corporate Officer (Senior Chief Technologist) and General Manager of the Intellectual Property Dept.  He also served as a Co-Chair of the CEE Committee of the LES International (2006-2008).  He is a Director and a Board member of the LES Japan (2006-2008, 2010- ), and a member of the LES USA/Canada, AIPPI-Japan and the Chemical Society of Japan.  He was a Director of the Industrial Property Cooperation Center (Japan) (2004-2008), a Councilor of the Japan Patent Information Organization (1999-2008), and a member of the Committee on Intellectual Property and a member of its Sub-Committee on Policy Planning of the Nippon Keidanren (2004-2007).  He received his Doctorate, Master and Bachelor of Engineering Degrees (Chemical Enginnering) from Tokyo Institute of Technology.  

[back to top]

Niels Hölder
Niels Hölder is an attorney at law and certified IP specialist lawyer focussing on patent litigation, licensing, unfair competition disputes, supplementary protection certificates, pharmaceutical data protection and market exclusivity.  He holds an LL.M. in Intellectual Property (Exeter/Dresden) and earned his doctoral degree in the field of cross-border patent enforcement. He represents and strategically advises clients in international patent disputes in all fields of technology. Before joining Hoffmann Eitle's patent litigation group as a trial lawyer in 2008, Niels Hölder worked with Baker & McKenzie and Vossius & Partners in Berlin, Frankfurt, London and Chicago. He has published numerous articles in the field of intellectual property and regularly gives lectures on patent and civil procedure law.

[back to top]

Chris Holman
Chris Holman is an associate professor of law at the University of Missouri-Kansas City School of Law.  He teaches and writes primarily in the areas of intellectual property, biotechnology and antitrust law, with a focus on the interface between patents and biotechnology.  Prior to becoming a law professor, he served as vice-president of intellectual property and patent counsel at several Silicon Valley biotechnology companies. He was also an associate at a major intellectual property law firm. A native of California, Professor Holman received a Ph.D. in biochemistry and molecular biology from the University of California at Davis, and engaged in post-doctoral drug discovery research at Roche Biosciences in Palo Alto, California. He attended law school at UC Berkeley's Boalt Hall.  

[back to top]

Mark S. Holmes
Mark S. Holmes is the founder and C.E.O. of PatentBridge LLC a privately held patent brokerage firm in Silicon Valley that specializes in select patents covering extraordinary scientific and industrial breakthroughs. He is co-chair of the Silicon Valley Chapter of LES.

Mr. Holmes has advised Visa, Sony, Applied Materials, Intergraph (in its $500,000,000+ settlement in Intergraph vs. Intel), Biosite, Fairchild Semiconductor, Rigel Pharma, Yamanouchi Pharma and the University of California at Berkeley (Berkeley Lab), as well as startups.

Mr. Holmes co-founded a successful startup which was sold to the Alabama state employees retirement fund (RSA) in the late 1990's.

He is also an active angel investor and advisor to technology startups.

He is a registered patent attorney, holds an engineering degree from Brown, is a member of the Institute of Electrical and Electronics Engineers (IEEE), and wrote the book Patent Licensing: Strategy, Negotiation & Forms (PLI).

He speaks nationally on the commercialization of intellectual property for the Practising Law Institute (PLI), Renaissance Weekend, Washington State Patent Law Association, Oregon Patent Law Association and other organizations.

[back to top]

Jackie Hutter
Jackie Hutter, MS, JD is a self-described 'Recovering Patent Attorney' who is one of the pioneering ranks of Intellectual Property ('IP') Strategists with over 15 years of experience counseling corporations, universities, entrepreneurs and investment professionals in all facets of IP creation, protection and enforcement.  Jackie is Chief IP Strategist of The Hutter Group LLC, a leading provider of IP-related business and investment consulting services to innovation-driven organizations of all sizes seeking to maximize their greatest form of business value-intangible assets.  In 2009 and 2010, Jackie was named one of the 250 top IP Strategists in the world by Intellectual Asset Management magazine.  Jackie was also named a SuperLawyer® in IP in Georgia in 2004, and she is a frequent speaker on IP strategy to business and legal professionals.  Jackie earned an M.S. in Pharmaceutical Sciences and B.S. in Chemistry and Mathematics and she spent several years as practicing chemist.

[back to top]

Mason (Skip) Irving, III
Skip is a Partner and Managing Director of Health Advances, LLC, a 60 person, healthcare product-focused, management consulting firm based in Weston, Massachusetts.  Skip has spent the last 20 years advising companies on business strategy, technology commercialization, and partnering in the medical products industries. 

Prior to joining Health Advances, as Vice President for Commercial Development at the Massachusetts Biotechnology Research Institute (MBRI), Skip was involved in the founding of seven life sciences companies.

Prior to MBRI, Skip was Vice President and Director of Worldwide Healthcare Consulting at Arthur D. Little, Inc. where his professional work involved technology planning, R&D management, and strategic alliances.  Working from ADL's Brussels office, Skip founded ADL's European Pharmaceutical Practice.   Skip also worked for Astra Pharmaceutical Products, Inc.  Skip graduated from the Massachusetts College of Pharmacy and earned his MBA at the Amos Tuck School at Dartmouth College.

[back to top]

David Jarczyk
David Jarczyk is COO of ktMINE, an intellectual property data and information services firm.  David has extensive experience conducting functional, risk, comparable company and economic analyses in a variety of industries. He also has expertise in performing business enterprise and intangible property valuations, as well as performing financial analyses and benchmarking on an individual company and industry-wide basis.  David set the vision for ktMINE's Royalty Rates and Records offering from his expertise in performing various transfer pricing services for multinational companies for tangible, services and intangible property transactions.    David has published numerous articles including "How appraisers can ‘get it right' in reasonable royalty cases," Business Valuation Update, January 2010. His speaking engagements include 'The Impact of The Transfer Pricing Service Regulations" presented at various conferences. 

[back to top]

Dave Johnson
David A. Johnson, PhD, Director External R&D, Oncology has been at Amgen since 2004.  Previous to that he was emplyed at Eli Lilly where he held positions in Licensing and in basic research, starting in 1984. He received his doctorate degree in Microbiology and Immunology from Temple University.

[back to top]

Gary K. Jones
Gary Jones is the Washington DC Representative for the Federal Laboratory Consortium for Technology Transfer (FLC), a position he has held since 2005.  As the DC Representative, Mr. Jones is responsible for providing FLC coordination in the DC area with Federal Agencies and their laboratories, Congressional staff, and trade, professional and other organizations.  He brings over twenty-three years of professional experience to his current position, including seven years in academia and over sixteen years in industry and government.  Most recently, Mr. Jones was on the faculty of American University's Washington Semester Program, where he served as an Academic Director for International Business & Trade.  He has also lectured on global R&D management in the George Washington University graduate business program, and served as an adjunct faculty member at University of Maryland University College, Graduate School of Management & Technology.  Prior to his academic experience, Mr. Jones' career included work as an exploration geophysicist in the energy industry, a policy analyst supporting the U.S. Department of Energy, and a researcher with the Virginia Department of Economic Development.  He holds an M.B.A from University of Richmond, a B.S. in Geophysics from Virginia Polytechnic Institute and State University, and has studied technology management and international business at the post-graduate level.

[back to top]

Paul Jones
Although Paul Jones lives and practices law in Toronto, Canada he does more work related to China than to Canada, and most of his clients are not Canadians. He speaks frequently on Chinese and Russian legal matters, as well as international licensing, distribution and intellectual property law issues. Currently he is writing a chapter on "Investigative Processes" under China's new Anti-Monopoly Law for the ABA Antitrust Section with Professor Huang Yong of Beijing, and developing a seminar with the head of the Russian Anti-Monopoly Service. In the past he has assisted both the governments of China and the U.S. with respect to the other government's legal system.

[back to top]

Syed Kazmi
I work as Vice President, Business Development & Strategic Planning at Ligand Pharmaceuticals.since 2007. From 1995 until 2007, I held various positions at Ligand, including Senior Scientist in Molecular Endocrinology, Director of Project Management and leader of multiple drug development teams, and Senior Director of Business Development. Prior to joining Ligand, I worked in discovery research at Johnson & Johnson from 1988 to 1995, where my most recent position was Principal Scientist in endocrinology and inflammation drug development programs. From 1985 to 1988, I held postdoctoral research positions at McMaster University, Hamilton. I received a PhD in biochemistry from J.N. University, New Delhi, and an executive MBA from San Diego State University.  

[back to top]

John Keagy
John Keagy is the CEO and Founder of GoGrid, the World's leading specialist in delivering cloud computing, also known as 'infrastructure on-demand' or 'Infrastructure as a Service'.  Among many industry leading features, GoGrid's Service Level Agrement is more detailed in the technical nature of what it covers and also more generous and, most importantly, easier to understand.  Prior to starting GoGrid, Keagy has started 13 companies with over half achieiving success.  Keagy is an Alum of UC Berkeley and is an avid instrument rated multi-engine pilot.

[back to top]

George Keller
George Keller specializes in technology license monitoring and enforcement at the NIH Office of Technology Transfer.  He has negotiated numerous license agreements and assured compliance of NIH licenses during his fifteen years at OTT.  Prior to OTT, he provided consulting services to companies developing diagnostic tests for infectious diseases and molecular biology research reagents.  Dr. Keller provided advice on, and management of grant proposals, patent applications, technology licensing, technical due diligence, research, product development groups and business development.  A graduate of the University of Maryland with a B.S. Degree in chemistry, he also earned a Ph.D. Degree in Biochemistry from Penn State, and conducted post-doctoral research on cystic fibrosis under an American Lung Association Fellowship.  He also served as a Senior Staff Fellow in Clinical Hematology at the NIH, working in the area of human gene regulation.

[back to top]

Bill Killian
Bill Killian is Senior Director, Corporate Licensing and Acquisitions, currently supporting the Nutrition business at Abbott Laboratories.  Over his thirty year career at Abbott, he has served in various technical and commercial roles of increasing responsibility in the Pharmaceutical, Diagnostic and Nutrition operating divisions of Abbott.  For the past 15 years, Bill has focused on business development where he identifies and negotiates deals to acquire or license various businesses or technologies. 

Since 2000, he has closed over 50 deals with global companies which included numerous licensing, collaboration and distribution relationships.

Bill earned a bachelors degree in chemical engineering from Purdue University.

[back to top]

Peter B. Kramer
Executive Director, manages Technology Transactions within the Strategic Transaction Group at Bristol-Myers Squibb. Technology Transactions is responsible for defining relationships and negotiating transactions with universities and companies to support BMS's internal R&D activities from target discovery through medicinal chemistry to clinical technologies. Dr. Kramer has over 25 years of experience in the pharmaceutical industry. He spent 10 years at Johnson & Johnson in technology evaluation and was the Assistant Director of Licensing for their biotechnology research group. After leaving J&J, Dr. Kramer was the Vice President of Business Development at a biotechnology company and a technology transfer officer at the University of Pennsylvania before joining BMS. Dr. Kramer received his BS from MIT, his PhD from Harvard University and his MBA from the Executive Program at Columbia University.

[back to top]

Katharine Ku
Katharine Ku is Director of the Office of Technology Licensing (OTL) at Stanford University.  OTL is responsible for the licensing of various state-of-the-art university technologies and industry sponsored research agreements, material transfer agreements and collaborations.   Ku was Vice President, Business Development at Protein Design Labs, Inc. from 1990-1991.  Prior to Stanford and PDL, Ku was a researcher at Monsanto and Sigma Chemical, and taught chemistry. Ku is active in the Licensing Executive Society (LES), serving as Vice President, Western Region and Trustee of LES.  She was President of the Association of University Technology Managers (AUTM) from 1988-90. She received the AUTM 2001 Bayh-Dole Award.  Ku has a B.S. Chemical Engineering (Cornell University), an M.S. in Chem. Eng. (Washington University in St. Louis).    

[back to top]

George Kyroudis
George is the Senior Director of Tax for Playboy Enterprises, Inc. based in Chicago, IL.  He is primarily responsible for all aspects of the company's global tax risk management, including policy, planning, financial reporting, compliance and audit defense.  George has over twenty years of experience in tax and accounting and has been with Playboy since 2006. He is a Certified Public Accountant licensed in Illinois and has an MS in Taxation from Golden Gate University.  Prior to joining Playboy, George held various senior positions with Accenture, KPMG, Information Resources, Inc.   Playboy Enterprises, Inc. is a publicly traded international multimedia entertainment company that markets the Playboy brand through a wide range of media properties and licensing initiatives. The company publishes Playboy magazine in the United States and abroad and creates content for distribution via television networks, websites, mobile platforms, and radio.  

[back to top]

Dooyong Lee
Dooyong Lee Executive Vice President, Acacia Technologies LLC  Mr. Lee joined Acacia in 2005 as Executive Vice President. He has over 25 years of experience in patent licensing and technology management with a long track record of success. He was previously Chief Operating Officer of Global Patent Holdings/TechSearch, which was acquired by Acacia. Prior to Global, he was President of LPS Group, a patent licensing company he founded under Information Holdings Inc. (now part of The Thomson Corporation, NYSE:TOC), that achieved profitability in less than two years. Prior to LPS Group, he co-founded FRI, an intellectual property consulting firm, then under the sponsorship of Fish & Richardson, PC and previously was a licensing executive at AT&T Bell Laboratories/Lucent Technologies. Mr. Lee received a B.A. from Oberlin College and an M.S. from the University of California, Berkeley (under a full fellowship).

[back to top]

Nick Lee
Nick Lee is a European Patent Attorney and a partner of the leading UK patent firm, Kilburn & Strode LLP.   His practice concentrates on the biosciences.  He is involved in all aspects of patent work, from the preparation and prosecution of applications in the UK, Europe and overseas to attacking and defending granted patents in opposition and appeal procedures at the European Patent Office, and from building patent strategies and providing advice on third party patents to carrying out due diligence exercises.   His clients include private individuals, universities, UK companies, overseas attorneys and large multinationals. Many of his UK clients are start-up companies.  His experience is not limited to the biosciences and he has dealt with a wide variety of patent and design work, including litigation, in the biotechnological, medical and mechanical fields.

[back to top]

Jeff Leedom
Jeff Leedom is a Partner at PricewaterhouseCoopers specializing in Licensing Management. He has been with PricewaterhouseCoopers for 15 years and advises clients on intellectual property matters.

[back to top]

Reid Leonard
Reid Leonard is Executive Director, Worldwide Licensing for Merck & Co., Inc. Based in Boston, Massachusetts, Reid provides guidance on Merck's licensing interests to biotechnology companies, academic institutions, and venture firms. He serves as an initial contact for the scientific evaluation of partnership opportunities through which Merck may collaborate to develop novel therapeutics. Reid's area of responsibility includes the Northeastern United States and Latin America. He also supervises search and evaluation efforts in Canada and India.

Dr. Leonard graduated from Brandeis University with a B.A. in biology and psychology. He earned a Ph.D. in biology from Purdue University and completed postdoctoral training in molecular pharmacology at Caltech. He joined Merck Research Laboratories in 1989 to conduct discovery research on ion channels. After ten years at the bench, Reid joined Merck's licensing group where he has contributed to the identification and execution of academic and biotech partnerships to advance Merck's pipeline

[back to top]

Jason Levin
Mr. Levin joined BrainCells in March 2009 from Jazz Pharmaceuticals, Inc., a neurology and psychiatry focused specialty pharmaceutical company which he joined in 2003. He brings more than 15 years of experience in the life sciences industry to BrainCells. During his time at Jazz Pharmaceuticals, Mr. Levin served in positions of increasing responsibility most recently as its Vice President, Corporate Development where he was responsible for licensing, acquisitions, corporate strategy and strategic alliances. Prior to joining Jazz Pharmaceuticals, he served as Director, Business Development at ALZA Corporation, a wholly owned subsidiary of Johnson and Johnson. In this role, Mr. Levin participated in ALZA's drug delivery technology in-licensing and out-licensing efforts. Previous to ALZA, he was responsible for business development at an early stage medical diagnostics company in Austin, Texas following four years in The Woodlands, Texas as a gene expression scientist at GeneMedicine, Inc.  

[back to top]

Russ Levine
Mr. Levine is a Partner at Kirkland & Ellis LLP where he specializes in patent infringement litigation and patent licensing.  His practice includes Section 337 litigation before the U.S. International Trade Commission.  He holds a B.S. in Interdisciplinary Engineering and a B.S. in Economics, both degrees from the University of Michigan.  He received his law degree from the University of Chicago.  Mr. Levine is registered to practice before the United States Patent and Trademark Office and he is a Certified Licensing Professional.  Mr. Levine is chair of the LESI Dispute Resolution committee and a Trustee of LES (USA & Canada).  He is a member of the LES, the ABA, the Federal Circuit Bar Association and the International Trade Commission Trial Lawyers Association.  He also is the Chair of the President's Council at Chicago's Museum of Science and Industry.

[back to top]

Steven D. Levitt
 Bestselling Author, FREAKONOMICS
 Author of the Highly Anticipated Follow-Up Book, SUPERFREAKONOMICS (Pub Date 10.20.09)
 FREAKONOMICS Spent Over 2 Years on The New York Times Bestseller List, With More Than 4 Million Copies Sold Worldwide
 The Popular FREAKONOMICS Blog is Hosted Exclusively on The New York Times Website

When mild-mannered economist Steven D. Levitt published a paper linking a rise in abortion to a drop in crime, it set off a firestorm of controversy and had both the conservatives and liberals up in arms. But Levitt has no political agenda and is the last person to be called a moralist. He is a brilliant but uncomplicated man who uses simple questions to reach startling conclusions. The Wall Street Journal has said "If Indiana Jones were an economist, he'd be Steven Levitt," he has shown other economists just how well their tools can make sense of the real world.

Steven Levitt is a tenured professor in the University of Chicago's economics department (he received tenure after only two years) and is the recipient of the American Economic Association's prestigious John Bates Clark Medal - given to the country's best economist under 40.

When Stephen Dubner (co-author of FREAKONOMICS and SUPERFREAKONOMICS) profiled Levitt in The New York Times Magazine, he was beset by questions, queries, riddles and requests-from General Motors and the New York Yankees and U.S. senators but also from prisoners and parents and a man who sold bagels. A former Tour de France champion called him to ask his help in proving that the current Tour is rife with doping; the Central Intelligence Agency wanted to know how Levitt might use data to catch terrorists.

Originally published in the U.S. in 2005, FREAKONOMICS instantly became a cultural phenomenon. Hailed by critics and readers alike, it went on to spend more than two years on The New York Times bestseller list, having sold more than 4 million copies around the world, in more than 30 languages. Levitt and Dubner have appeared widely on television and maintain the popular FREAKONOMICS blog, which can be found on The New York Times website.

A self-effacing, mid-western father of four, Levitt has an enormous curiosity and is set on course by personal experiences and the incongruities he sees in everyday life. He is an intuitionist. He sifts through a pile of data to find a story that no one else has found and devises ways to measure an effect that veteran economists have declared un-measurable.

Through forceful storytelling and wry insight, Levitt shows how economics is, at root, the study of incentives – that is, how people get what they want, or need, especially when other people want or need the same thing. FREAKONOMICS shows that the modern world, despite a great deal of complexity and downright deceit, is not impenetrable, is not unknowable, and-if the right questions are asked-is even more intriguing than we think. All it takes is a new way of looking.

His unconventional wisdom continues with SUPERFREAKONOMICS, which he and co-author Stephen Dubner spent the past four years researching. SUPERFREAKONOMICS is even bolder, funnier, and more surprising than the FREAKONOMICS, and is destined to be a bestseller. The book delves into the biggest issues of our time: healthcare, terrorism, global warming, the current financial crisis, and much more. In his presentations around the globe, Levitt presents results from his research and tailors his remarks to the specific needs and objectives of your organization, all with a healthy dose of humor!

[back to top]

Terry Ludlow
Terry Ludlow, Founder, Chairman and Chief Executive Officer (CEO), is a recognized pioneer in semiconductor reverse engineering, and was among the first to realize its value for Intellectual Property (IP) groups and technology teams. He founded Chipworks in 1992 to offer semiconductor and microelectronics system reverse engineering services to companies seeking to build a competitive advantage, and protect and grow the potential of their intellectual property. As CEO, Terry continues to provide the strategy, vision, and driving force that have earned Chipworks its position as the premier source of knowledge of what's inside technology.  

[back to top]

Jason Lye
Dr. Lye is the Director of External Business Development - Technology Assets for Newell Rubbermaid, Inc.  His responsibilities include driving growth through identification of strategic new business opportunities with external partners that involve technology transfer. Dr. Lye holds a Ph.D. in Fiber and Polymer Science from North Carolina State University, and a BSc. in Colour Chemistry from The University of Leeds in the UK.  Prior to joining Newell Rubbermaid's External Business Development team, Dr. Lye's background includes business development experience with Kimberly-Clark Corporation as well as digital imaging research with both Kimberly-Clark and Imperial Chemical Industries Ltd.    Newell Rubbermaid Inc. is a global marketer of consumer and commercial products with sales of $5.6 billion and a strong portfolio of brands, including Rubbermaid®, Sharpie®, Graco®, Calphalon®, Irwin®, Lenox®, Levolor®, Paper Mate®, Dymo®, Waterman®, Parker®, Goody®, Bernzomatic® and Amerock®.

[back to top]

Robert MacKenzie
Robert MacKenzie – VP Business Innovation - Techlink Entertainment Robert MacKenzie began his career in 1987 when he founded Bay Industrial & Mine Tech Inc. (BayTech), an electronics research, development, and manufacturing company in Sydney, Nova Scotia.  Mr. MacKenzie was responsible for the invention of two core technologies from which more than 20 products were commercialized.  In 1997, he was awarded the CANMET Technology Transfer Award, for an exceptional and distinguished contribution to technology transfer of benefit to the Canadian Minerals and Metals Industry.  Mr. MacKenzie has considerable experience in the areas of electronic manufacturing and design, marketing and sales.  Mr. MacKenzie began his tenure at Techlink Entertainment as the Product Manager.  He is co-inventor on two patents regarding Responsible Gaming technologies.  He held the post of Chief Operating Officer in 2002, and his current position is the VP Business Innovation, which includes the corporate activities in patents, trademarks and technology licensing.

[back to top]

Todd MacLaughlan
Todd was responsible for international marketing for  the $200M global cardiovascular products for Searle including developing pre-commercial launch plans for eplerenone.  Todd led the marketing efforts for the GI business (misoprostil) for Searle Canada and the contact lens business for Allergan Canada.  Todd was head of North American business development at Bayer and Global business development at Watson pharmaceuticals. While in business development roles he completed over 50 transactions including the Allicense biotech deal of the year between Monsanto and Millenium, the ground breaking $1.3 billion authorized generic deal between JNJ and Watson and others. He was also the General Manager for the $300 million outsourcing businesses at Cardinal Health (injectable and biotech) and at Cephalon (Cima Labs) where he oversaw the $75 million fast dissolve ODT business.  Currently Todd is the SVP of Business Development at inVentiv Health.

[back to top]

Robert S. MacWright
Robert MacWright is a partner in the Washington, DC office of Frommer Lawrence & Haug LLP.
Dr. MacWright is a registered patent attorney, and his practice focuses on technology licensing and other intellectual property-related transactions, and on the preparation, prosecution and litigation of patents in the biotechnology and pharmaceutical fields. He is widely recognized for his experience, innovation and leadership in the field of academic technology transfer.

Prior to joining Frommer Lawrence & Haug LLP, Dr. MacWright was Executive Director, CEO and Chief Patent Counsel of the University of Virginia Patent Foundation, which protects and licenses inventions made in the course of research at the University of Virginia. Under his leadership, the Patent Foundation came to manage about 180 new inventions and complete about 60 licenses and other agreements with industry each year. He is a strong supporter of faculty start-up companies, and created Spinner Technologies Inc. as a subsidiary of the Patent Foundation to encourage and support young companies based on University of Virginia inventions. He also led the creation and development of the Jefferson Corner Group, a local angel investment fund. In addition, Dr. MacWright was adjunct professor at the University of Virginia School of Law, where he created and led the UVA Patent and Licensing Law Clinic to give UVA law students first-hand experience with patents and licensing. In 2004, Dr. MacWright and the staff of the Patent Foundation published a comprehensive Operating Manual that has provided insight and guidance to academic technology transfer offices around the world.

Prior to joining the Patent Foundation, Dr. MacWright practiced law at two prominent law firms in New York City, where he represented corporate and academic clients in drafting and negotiating licenses, joint venture agreements and distribution agreements, and also in patent litigation and patent application preparation and prosecution. He also evaluated the intellectual property assets of companies being financed or acquired. Before practicing law, Dr. MacWright launched the first in-house technology transfer program at Rutgers University, and served as Executive Director of the Office of Corporate Liaison and Technology Transfer.

Dr. MacWright received his undergraduate degree from Rider College in New Jersey and received his Ph.D. in biochemistry jointly from Rutgers University and the University of Medicine and Dentistry of New Jersey. He received his J.D. with high honors from Rutgers School of Law – Newark.

Dr. MacWright's Ph.D. thesis work was aimed at determining the primary and secondary structure of human Type IV collagen. Following his graduate studies, Dr. MacWright carried out post-doctoral research on the structure and function of T7 RNA Polymerase, and later became senior scientist for a biotechnology company where he developed small and large scale enzyme purification processes.

Dr. MacWright is a frequent speaker at meetings of the Association of University Technology Managers (AUTM), the Licensing Executives Society (AUTM) and the Association of European Science and Technology Transfer Professionals (ASTP), often delving into the more complex, unusual and challenging aspects of technology licensing and patent litigation, and into the impact of emerging case law, statutes and regulations on licensing strategies and tactics.

[back to top]

Jeet Mahal
Jeet Mahal is the Head of Corporate Development at Portola Pharmaceuticals.  Jeet played an instrumental role executing the company's Phase 2 partnerships with Novartis and Merck,  including leading scientific diligence efforts, leading deal analytics and playing an extensive role in final negotiations.  Prior to Portola Pharmaceuticals, he was Director, Business and Corporate Development at Scios/Alza (Johnson & Johnson) where he led analytics and life cycle management for the company's Phase 3 Factor Xa (rivaroxaban) program and commercial analytics for US cardiovascular in-licensing.  Prior to Scios, Jeet held various business and product development positions of increasing responsibility at Navigant Consulting, Lumicyte Inc and COR Therapeutics.    Jeet holds bachelors and masters degrees in Molecular Biology, a masters degree in Computer Science and an MBA. 

[back to top]

J. Derek Mason, Ph. D.
J. Derek Mason is a partner in the Chemical Practice Group of Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P. in Alexandria, Virginia.  His practice focuses on client counseling, IP issues in corporate transactions, portfolio management, licensing, and patent preparation and prosecution, with experience in a wide range of chemical and related areas, such as medical and biotech diagnostics, polymers, textiles, and pharmaceuticals, for both international and domestic clients.

Dr. Mason received his Law degree from the George Washington University National Law Center. He holds a Doctorate in Chemistry from the University of Wisconsin, where he studied organometalloid chemistry. He received his Bachelor of Science with Highest Honors in chemistry from the University of North Carolina, where he also performed undergraduate research in the area of organic photochemistry. He has published and presented papers on his findings in both areas of research.

Dr. Mason is admitted to the Virginia Bar and the Bars of the Virginia Supreme Court, the U.S. Court of Appeals for the Fourth Circuit, the U.S. District Court for the Eastern District of Virginia and the U.S. Court of Appeals for the Federal Circuit. His association memberships include the American Bar Association, the Virginia Bar Association, the American Intellectual Property Law Association (AIPLA), the Licensing Executives Society (LES), and the American Chemical Society.

[back to top]

Damon C. Matteo
Damon C. Matteo joined PARC in 2003 as the Vice President of Intellectual Capital Management.  He leads all of PARC's intellectual property (IP) operations, including IP Creation, IP Legal, and external licensing relationships.  Specializing in leading-edge technology, Mr. Matteo has over fifteen years direct experience developing and implementing intellectual capital management strategies.  He brings to PARC extensive experience in the full-spectrum management of corporate intellectual capital assets, from optimizing their creation and capture, to extracting value from them through vehicles such as licensing and spin-outs.  Prior to taking his current role, Mr. Matteo led Hewlett-Packard's world-class licensing organization, directing intellectual property licensing for the entire corporation.  Mr. Matteo worked previously with PARC as the Xerox Licensing Manager in charge of IP licensing for PARC, Xerox's European Research Centers, and intellectual capital aspects of Xerox's spin-out and M&A activities.  Before joining Xerox, Mr. Matteo served as president of Savanteque Incorporated, a technology management consulting firm specializing in intellectual capital management.

[back to top]

James A. McCarthy, CLP™
Jim McCarthy is Senior Vice President, Corporate Development, for EGEN, Inc.; a biotechnology company specialized in nucleic acid delivery and therapeutics. Jim has thirty years of life sciences professional experiences. His background includes a twenty five year career with Bristol-Myers Squibb and Eli Lilly & Company and has spent over fifteen years in corporate business development and licensing roles. These efforts included projects in over 30 countries and resulted in over 50 completed agreements across a range of transactions (i.e. acquisitions, licensing, research agreements etc.) valued in excess of $700 million.

He holds an MBA from Indiana University, a B.S. from State University of New York Upstate Medical Center, and is a recipient of the Certified Licensing Professional (CLP™) designation. He has been a long term LES member and served as Chairperson in 2007 for the first "LES BioPharmaceutical Royalty Rate and Deal Terms Survey".

[back to top]

Andy McGee
J. Andrew McGee Andy is currently Manager, Corporate Business Development, at Eli Lilly and Company.  In this role, his primary responsibilities include serving as lead negotiator with potential partners as well as leading internal cross-functional teams through the corporate deal process.  He is responsible for in-licensing clinical and pre-clinical stage molecules, focusing on diabetes, oncology and Japan.  Andy's career in the pharmaceutical industry started at Pfizer, as a sales representative.  He joined Lilly in 1997.  Much of Andy's experience at Lilly has been in marketing as well as new product planning.  Andy's educational background is in the field of biology, where he holds both Bachelor's and Master's degrees from Purdue University.  He also holds a MBA degree from Duke University.  

[back to top]

Eileen McMahon
Eileen McMahon is the co-chair of Torys' Intellectual Property, and Food and Drug Regulatory Practices. She is one of a handful of Canadian lawyers who advise on regulatory clearance and IP protection of products in Canada. Eileen is recognized internationally as a leading cross-border practitioner in the areas of commercial agreements/licensing in the life sciences industry (drugs, medical devices, biologics, dietary supplements and natural health products). Her expertise spans commercial agreements, outsourcing, regulatory and IP. She has also been recognized in Chambers Global, Which Lawyer? Yearbook, Lexpert’s Guide to the Leading 500 Lawyers in Canada and Best Lawyers in Canada. She co-leads a course on healthcare licensing agreements and strategic alliance (accredited by the Canadian Healthcare Licensing Association and endorsed by the Toronto Biotechnology Initiative).  Eileen sits on the boards of various drug and biotechnology companies, & various industry and IP associations.

[back to top]

Tom Meagher
Tom Meagher is a shareholder in the Princeton office of Volpe & Koenig, P.C. . He has handled patent litigation for Agilent Technologies; Boston Scientific; Hewlett-Packard; Wang Laboratories; Nan Ya Plastics; and Microsoft, among many others. Mr. Meagher has also assisted General Electric, Princeton University, Thomson Licensing, and Wi-LAN V-Chip in patent licensing, and has managed patent prosecution. Mr. Meagher's professional background spans more than 30 years, including serving in the patent departments of RCA Corporation and ITT Corporation, and nearly two decades with Kenyon & Kenyon and five years with Duane Morris LLP. He is a member of the Intellectual Property Owners Association, the Licensing Executives Society, and the Association of University Technology Managers. Mr. Meagher has also lectured and written on patent issues facing universities. Mr. Meagher has a B.S. , Electrical Engineering, from Carnegie Mellon University, and a J.D. from Catholic University of America, Columbus School of Law.

[back to top]

Stewart Mehlman
Stewart K. Mehlman is currently Director - Licensing. Alliances & Emerging Technology for Praxair, Inc.  He holds bachelors and masters degrees from MIT in Materials Science and Metallurgy.  He has been with Praxair and its predecessors or subsidiaries for over 30 years holding a number of positions in industrial gas applications development, sales engineering, marketing, business development and on-site sales.  He also served as President of Praxair-Trailigaz Ozone Company for over 5 years.   In his current roll, he manages Praxair's intellectual property.  He was co-chair of the Industrial Research Insititute's (IRI) Research-on-Research project on Better Practices for Managing IP in Open Innovation. 

[back to top]

Rebecca Menapace
Rebecca Menapace is a Director at Partners HealthCare Research Ventures & Licensing (RVL).  Her team oversees the management and licensing of intellectual property and serves as the entry point for all industrial relationships relating to research, support of research or technology transfer.  Rebecca brings to RVL a strong background in corporate development, product management and product development within the biotech industry.  Following six years of laboratory and supervisory experience, including the issuance of two patents as a joint inventor, she went on to develop and manage products for the chromatographic separations division at Dyax Corp.  She further contributed her business skills toward the negotiation of licensing and acquisitions at Charles River Laboratories. She holds an MBA with a focus on High Tech from Northeastern University, and is a registered patent agent.  

[back to top]

Bernd Merkl
Bernd Merkl is Chief Business Officer (CBO) at GENEART AG, the leading company in gene synthesis and specialist in Synthetic Biology. In this role he is responsible for all business development, sales and marketing activities of the company. Prior to joining GENEART in 2005 he worked for Henkel KGaA in the area of research controlling and business development. Bernd Merkl holds university degrees in business administration and Biology / Chemistry. He combines expert knowledge in the area of strategic planning, business development and controlling with a vast experience in the commercialisation of biotechnological products.

[back to top]

Jeremy D. Middleton
Jerry joined Elusys in 2007 as Vice President, Corporate Development. Previously, Jerry was Vice President of Business Development at Valera Pharmaceuticals. While at Valera, he led all business development, strategic planning and project planning activities. Prior to Valera, he was with Neose Technologies initially as Director, Commercial Development, then Senior Director, Commercial Development, followed by Vice President, Commercial Development, Manufacturing and Facilities. While there, he was responsible for leading the commercial development, manufacturing and facilities functions, including the development of overall corporate business strategy. Jerry also held various positions with Abbott Labs/BASF Pharma, The Boots Company and Doverstrand Ltd. Jerry holds a BS from DeMontfort University in England.

[back to top]

Lesley Millar
Lesley Millar has served as the Director of the Office of Technology Management (OTM) at the University of Illinois at Urbana-Champaign since 2006 after serving as Interim Director for most of 2005. As Director, Ms. Millar leads the technology transfer team responsible for the identification, protection, marketing and licensing of intellectual property arising from the more than $500 million in research conducted on campus.

Prior to joining the OTM, Ms. Millar had an extensive career in government in England. Her direction during 13 years of service as a Section Leader for Information Technology Strategy and Consulting in the Bristol City Council involved interactions with both national government and local community leaders. Ms. Millar also oversaw a team managing the introduction of new legislation to the Bristol city council, and was subsequently responsible for the award, implementation, and management of contracts across a range of service areas.

A native of Scotland, Ms. Millar earned a bachelors degree in Education in Edinburgh, a masters degree in Education at the University of Georgia, Athens. While earning her MBA at the University of Illinois at Urbana-Champaign, Ms. Millar also served as the Executive Student Director of OSBI Consulting, where she managed operations of the consulting arm of the MBA program.

[back to top]

John Mohr, CPA, CLP™
John is a multi-dimensional drug industry executive with expertise in managing emerging company issues. His distinguished career includes management of multi-million dollar brands and building products from 'bench-to-market'. His career includes 12 years at Merck where he lead Financial Services for Merck's North America Operations followed by six years of responsibility in Marketing & New Product Planning for CNS and GI Products, including worldwide marketing franchise head for the blockbuster brand Pepcid®.  He was President of Fournier Pharma (US) where he build a strategic partnership with Abbott for TriCor, now a $1.5 billion CV brand.  Most recently he led Business and Corporate Development at CV Therapeutics leading to a major agreement with Menarini and managing the $1.4 billion M&A transaction with Gilead.

Tanya K. Moore
Tanya Kaptsan Moore is a General Manager of Outbound IP Licensing in Microsoft's corporate Intellectual Property & Licensing group. Her responsibilities include formulating outbound technology licensing strategies, identifying and negotiating licensing arrangements in various Microsoft technology areas, including financial valuations, and leading a team of licensing executives. In her IP career, she has led and participated in a wide variety of transactions involving the licensing of patents, know-how, copyrighted materials, and trademarks, as well as asset sales, divestitures and joint ventures. 

Prior to assuming her position with Microsoft, Ms. Moore was a key member of IBM's Intellectual Property & Licensing organization. Ms. Moore joined IBM in 1980 and spent the early part of her career in software development for a number of IBM's operating systems. She has held numerous technical positions, including project and quality management, where she received many awards. During this time, she also served as an adjunct instructor at IBM's Software Quality Institute. She has held a number of technical management positions in applications and systems software product development, transitioning in the mid-nineties to the business side of IBM, initially in server group OEM sales and later joining the IBM corporate IP group. In late 2003, Ms. Moore left IBM to join the Microsoft IP team.

Tanya Kaptsan Moore holds a Bachelor of Arts degree in Mathematics from Fordham University, and a Master of Science degree in Computer Science from Polytechnic University.  Ms. Moore is a member of the Licensing Executives Society (LES), and is the Secretary and Board Member of the LES Foundation, Inc.

[back to top]

Christopher Morrison
Chris Morrison has covered the biotech and pharmaceutical industries for 11 years.  He is currently editor-in-chief, biopharmaceuticals at Elsevier Business Intelligence.  EBI publishes a variety of magazines and newsletters focused on biopharmaceutical strategy, business development, finance, regulation, reimbursement and policy, including IN VIVO and 'The Pink Sheet'.  Chris holds an undergraduate degree in neurobiology and behavior from Cornell University and a graduate degree from New York University in journalism and science writing.  

[back to top]

Charles Murray
Chip Murray leads the Intellectual Assets & Licensing business of DuPont, a position he assumed in April 2002.  The Managing Director of Intellectual Assets & Licensing has profit and loss responsibility for all out-licensing activities within the corporation.  Intellectual Assets & Licensing is chartered with leveraging and extracting maximum value for DuPont technology, intellectual property and knowledge.  Prior to his current position, he held management positions in DuPont's Polyester Enterprise, including most recently, assignments as Global Technology Director and Director of Strategic Planning for Dacron®.  His over 33-year career with DuPont has included assignments at many DuPont locations, and a variety of disciplines including Engineering, Marketing & Sales, Manufacturing and Technical leadership.  While Director of Strategic Planning for Dacron®, Chip negotiated strategic alliances or JV's with Unifi in USA, Akra Group in Mexico, Suzhou in PR China and Sabanci in Europe. 

[back to top]

Charles R. Neuenschwander
For eighteen years Mr. Neuenschwander has managed and supported client patent license negotiations and litigations for IPLC, LLC, Patent Solutions (both of which he co-founded), and others.  Mr. Neuenschwander directs and participates in developing licensing strategies, completing portfolio evaluations, documenting patent infringement incidents, calculating infringement damages and license royalties, and concluding license agreements.  He has clients and conducts negotiations in Asia, Europe and the United States.  He has testified as both a fact and expert witness before the International Trade Commission and in US Federal and State Courts.  Mr. Neuenschwander's licensing focus is in the areas of semiconductors, telecommunications, information technologies, consumer electronics, and software.

Mr. Neuenschwander speaks world-wide and participates in panel discussions both for the Licensing Executives Society (LES) and Continuing Legal Education seminars.  He is designated an LES Certified Licensing Professional (CLP).  Mr. Neuenschwander is a US delegate to the LES International organization.  His writings have appeared in numerous publications such as the Licensing Journal and les Nouvelles and he has been a guest columnist for IP Law360.

[back to top]

Fiona Nicolson
Fiona Nicolson is a solicitor and a  senior  IP transactional partner with London based law firm Bristows which is well known internationally for its work with IP rich companies and institutions, Fiona has many years  of experience in advising on  international licensing deals  working with a wide range of clients in a number of industries including life sciences, high tech, clean tech, consumer goods and academia

[back to top]

Chris Noble
Christopher Noble is MIT's Licensing Officer for energy technology. He previously worked for twenty-five years in energy and technology companies ranging from the Fortune 500 to startups. Chris has been a tech startup founder, is the lead inventor on two issued patents, has raised and negotiated multiple VC financings, and has served on the Board of several private companies. He lived and worked in South America and Europe and is fluent in French and Spanish. Chris's activities currently include serving on the Board of Design that Matters, a non-profit product design company focused on health and education needs in developing countries. He has a B.Eng. from McGill University and an MS in Management from MIT.

[back to top]

Brian O'Shaughnessy
Brian O'Shaughnessy is a shareholder, and Chair of the Chemical and Pharmaceutical Patent Practice Group of the law firm Buchanan Ingersoll & Rooney.  He has been practicing patent law for over 20 years, both in-house and in private practice.  His practice focuses on licensing, litigation, interferences, and patent portfolio management.   He is a Trustee of the Licensing Executives Society, USA & Canada; and a contributing author and faculty member of the LES Professional Development Series.  He also serves as a member of the Board of Trustees of his alma mater, Rochester Institute of Technology.  

[back to top]

Stasia Ogden
Stasia Ogden is the Assistant General Counsel, Intellectual Property, Biotech for Baxter Healthcare Corporation in Deerfield, Illinois. Prior to joining Baxter, Stasia served as Associate Chief Intellectual Property Counsel with Becton, Dickinson and Company, Senior IP Counsel, Life Sciences Business Unit with Motorola, Inc. , Assistant General Counsel, IP with Monsanto Company, and a Patent Attorney with Johnson & Johnson. Prior to that, she worked at the law firms of Finnegan, Henderson, Farabow, Garrett & Dunner and Cushman, Darby & Cushman. Stasia received a B.A. in Biochemistry from Northwestern University, completed Ph.D. course work in Immunology at the Johns Hopkins University School of Medicine, received her J.D. from Georgetown University Law Center, and her M.B.A. from the University of Missouri, St. Louis.

[back to top]

Cat Oyler
Cat Oyler is Sr. Director, Emerging Technologies in the Corporate Office of Science and Technology at Johnson & Johnson.  Cat joined Johnson & Johnson from AstraZeneca where she was responsible for evaluating and in-licensing clinical and marketed oncology products.  Additionally, Cat led the business development effort for out-licensing of AstraZeneca's oncology assets and assisted with strategic planning for oncology business development.  Prior to joining AstraZeneca, Cat served in a progression of business development roles at Myriad Genetics, culminating in leading all diagnostic licensing for the Myriad Genetic Laboratories division of the company.  With over ten years of BD experience and more than 15 years of biotech experience, Cat has also previously held marketing and research scientist roles at Amgen, Alza and Alkermes.  Cat received a bachelor's degree in Biology from Williams College and an MBA from the UCLA Anderson School of Management.

[back to top]

Daniel Papst
Daniel G. Papst graduated from the University of Karlsruhe in electrical engineering and information technology in 2000, earning a Dipl.-Ing.. He gained his first legal experiences as an intern at the law firm of Welsh & Katz Ltd in Chicago in early 2000. Thereafter, he undertook the formal training to become a German patent attorney at the IP law firm Reinhard Skuhra Weise & Partner GbR in Munich. Mr Papst has been a licensed German patent attorney and has worked with Papst Licensing GmbH & Co KG in St Georgen since 2005. He is one of the firm's managing directors and shareholders.

[back to top]

Wendy Pan
Wenseng "Wendy" Pan is a seasoned business attorney. She advises multinational pharmaceutical companies, biotech startups, specialty pharmas, and medical device companies in structuring and negotiating all phases of complex commercial transactions. Her practice covers early stage research collaboration, product and technology licensing, and global alliance formation for product development and commercialization, as well as asset acquisition and divesture, manufacturing, and supply agreements. As a former scientist and a registered U.S. patent attorney, she provides unique perspective in resolving business and patent issues in commercial transactions relating to small molecular drugs, biologics, medical devices, protein- and antibody-related platform technologies, and drug-delivery technologies. She also has significant experience private investments and mergers and acquisitions (M&A) and the aggregate value of the M&A transactions she has advised is above $10 billion.

[back to top]

John Paul
John Paul is a partner in the Washington, DC office of Finnegan Henderson and chairs the firm's IP management section.  He has over 25 years of experience in intellectual property licensing, litigation, and prosecution and currently focuses on strategic planning, due diligence investigations, and licensing of IP portfolios.   Mr. Paul has set up and directed licensing and enforcement programs that generated significant royalty revenue for leading technology companies. And he had conducted numerous due diligence investigations to identify, evaluate, and protect proprietary technology positions during startup, financing, product development, licensing, and acquisitions.   Mr. Paul frequently lectures and writes on IP issues and is a trustee and vice president of LES US/Canada. 

[back to top]

Clay Phillips
Clay joined General Motors in 1986, and has focused his work on international business development, product planning, strategy and intelligence.  He advanced through analyst positions at GM Headquarters in Detroit, Michigan, planning manager positions at the GM Europe Headquarters in Zurich, Switzerland, and executive positions in export operations, corporate planning, business development, alliance management, and intelligence in Detroit and the R&D Center in Warren, Michigan.  In his current role as the Director for Strategic Initiatives, he oversees a team evaluating technology start-ups for GM Ventures LLC, a recently formed corporate venture capital arm of GM. Prior to General Motors, Clay served with the US Navy as an Intelligence Officer. Clay holds a BA from Trinity College in Hartford, Connecticut, and an MBA from Columbia University in New York City.

[back to top]

Ruth Plager
Ruth Plager, President, ZenithBIO LLC, a Strategic Business Development Consultancy, provides a range of services designed to accelerate the business development goals of young, dynamic biopharmaceutical companies. In more than a decade of consulting, we have provided critical insights and analyses that strengthened the negotiating positions of our clients, primarily in the major biotech hubs.

Our clients benefit from my 25 years of commercial experience across all therapy areas, and early experience at Pfizer, Syntex, and Enzon.

As an active LES HealthCare member, Ruth has been involved in developing panels and presentations for LES HealthCare Programs, which included

  • Repositioning In-Licensed Assets to Increase Commercial Potential
  • Negotiating Mechanism Based Alliances
  • Impact of Funding Options on Licensing Deals
  • Anatomy of a Deal: Four Deals That Highlight Novel Solutions to Complex Issues
  • Reverse Mergers-Gaining Funding and Public Access without an IPO
    (LES Annual, Oct. 2009)
  • Game Theory Applications to BioPharma Deal Negotiations

Ruth received her B.S. Degree from the University of Wisconsin. She spent a year in Cancer Research at the Weizmann Institute of Science, in Israel, and in addition, attended a series of Health Economics courses at Stanford's Graduate School of Business.

[back to top]

Michael Plonka
Michael assists businesses through challenges in strategy, planning deployment and execution of initiatives, as well as with obtaining government credits and refunds for research and development expenditures. Michael has also prepared patent applications and opinions and has collaborated with builders and manufacturers to design electrical systems and coordinate corresponding construction documents since he graduated from the University of Toronto with a B.A.Sc. in electrical engineering. Michael is a licensed professional engineer and is currently pursuing registration as a Canadian patent agent and certification as a licensing professional.

[back to top]

Casey Porto
Casey Porto is Sr. V.P. for Commercialization and Deployment at the National Renewable Energy Laboratory (NREL), managed for the U.S. Department of Energy by the Alliance for Sustainable Energy, LLC, a partnership of Midwest Research Institute and Battelle Memorial Institute. She leads a new, $50 Mil organization  responsible for moving new technologies into the marketplace, and achieving broad market adoption of existing energy efficiency and renewable energy solutions. Casey was previously Director of Technology Transfer at Oak Ridge National Laboratory (ORNL), a $1 Bil DOE laboratory managed and operated by UT-Battelle, LLC. Prior to ORNL, Casey was A.V.P. for Technology Transfer and Executive Director of Case Technology Ventures (a $5 Mil pre-seed investment fund) at Case Western Reserve University. Prior to Case, she spent 6 years in Technology Transfer at Carnegie Mellon University, with the last 2 years as Director of the office.

[back to top]

Dr Stephen Potter
Stephen started his career as a chemist, taking his doctorate at the University of Sheffield in the UK. He won a Harkness Fellowship at Yale University followed by a Salter's Fellowship at Cambridge.

His industrial career started with ICI in the UK in technical and product management. It then oscillated between:

start-ups / small companies:
- Devex SA in Switzerland, where he was the CEO and owner
- QED Intellectual Property, part of the Scipher group in the UK, where he started the business and completed it by looking after Europe
- CU Chemie Uetikon in Switzerland, Germany and the US, where he was the CTO and also responsible for business development

and global businesses:
- WR Grace / Henkel in Switzerland and Germany
- Rexam in the UK, where he was the CTO.

He has operating experience in a wide variety of industries including (fine) chemicals, pharmaceuticals, electronics, automobiles, materials, printing and packaging and, latterly, intellectual property and licensing.

He likes to feel that he is an entrepreneur and is currently spending most of his time acquiring software and telecoms patents for Intellectual Ventures, a private US company, from major companies, SME's, academia and individual inventors.

He has just completed his term as the Chairman of the R&D Society in the UK, an organisation that helps all people interested in the R&D world network and learn….

He is married with 4 children and he and his wife have just moved back to Switzerland for their 3rd major house renovation project.

[back to top]

Guy Proulx
Guy L. Proulx Managing Director Transpacific IP  Mr. Proulx founded Transpacific IP in 2004 as an IP management and consulting company.  The company has built a substantial patent portfolio that includes a broad range of technologies.  Concurrently, Transpacific IP has expanded throughout Asia with offices in Taipei, Singapore, Hong Kong, Tokyo and Beijing.  The company is privately owned and funded.  Prior to founding Transpacific IP, Mr. Proulx was involved in all facets of business startup activities including company formation, business capitalization (equity/debt), strategic planning, and general management.  He has also worked with management on strategic IP issues including patent portfolio development strategy, maximizing licensing opportunities, and the acquisition of patents.  Additionally, he has provided management assessment expertise and due diligence assistance (including patent review) for private equity investors and acquisition groups. 

[back to top]

Linda Pullan
Linda M. Pullan, Ph.D. offers biotech and pharmaceutical companies consulting in all aspects of partnering through Pullan Consulting (www.pullanconsulting.com). She has over 20 years of drug industry experience, including drug discovery at Monsanto/Searle/now Pfizer and ICI/Zeneca/now AstraZeneca, in-licensing technology and drug candidates at what is now AstraZeneca and at Amgen as the head of oncology and hematology licensing, and also out-licensing and business development in a small company at Kosan Biosciences. For several years now, she has been providing companies help in identification, evaluation, valuation, negotiation and strategy for partnering in or out. She writes a free monthly newsletter Pullan's Pieces for about 2800 readers.

[back to top]

Dennis Purcell
Mr. Purcell has served as the Senior Managing Partner of Aisling Capital's Fund I and Fund II since February 2000 and is responsible for the management of the Partnership.

Prior to joining Fund I, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, "H&Q") for over five years, and served on the Executive Committee of Hambrecht & Quist. While at Hambrecht & Quist, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Mr. Purcell has also often been cited as one of the sector's leaders. He was honored in the "Biotech Hall of Fame" by Genetic Engineering News and named to the Biotechnology All-Stars list by Forbes ASAP. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell currently serves as a director of Dynova Laboratories, Inc. and Xanodyne Pharmaceuticals, Inc. Previously he served as a director of Aton Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc., Cengent Therapeutics, Inc., and Valentis, Inc. He is also a member of the Board of Directors of the Biotechnology Industry Organization (BIO) – Emerging Companies Section. He has served as a member of the Advisory Council at Harvard Medical School.

Mr. Purcell received his M.B.A. from Harvard University, and his B.S. in Accounting from the University of Delaware.

[back to top]

John T. Ramsay, Q.C.
John is a partner in the firm's Calgary office practising in the area of technology law. Acting as counsel to closely held businesses throughout his career and, since 1977, to developers and users of technology, particularly computer software, John has been rated by L'expert as one of Canada's leading lawyers in intellectual property and in computer law. He is also recognized in The Best Lawyers in Canada.

After receiving a business administration degree from the University of Western Ontario in 1963, John attended the University of Toronto, where he received a bachelor of laws degree in 1966. John was admitted to the Ontario and Alberta Bars in 1968, and appointed Queen's Counsel in 1998.

John is a member of the Law Society of Alberta, the Canadian Bar Association, the American Bar Association, the Canadian IT Law Association, Licensing Executives Society (U.S.A./Canada) Inc., Intellectual Property Institute of Canada and the Computer Law Association (U.S.A.).

A member of the Editorial Review Board of Les Nouvelles (writes the regular book reviews), the Journal of the LES and the American Bar Association's Information Security Committee, John is also Chair, Licensing Executives Society Summer Meeting 2001, and a former Vice President, Canada and Executive member of the Licensing Executives Society (U.S. and Canada), Inc.

A prolific writer, John is the author of the leading Canadian text, "Technology Transfers and Licensing" published by Butterworths, 1996; "Trade Secrets in Canada" (a chapter in Worldwide Trade Secrets, published by Clark Boardman), "Drafting Confidential Agreements in Canada," published in the Intellectual Property Journal, 1988. John was also co-author of "Shareholder Agreements" in the Alberta Corporations Manual. John has made numerous presentations, including: "Commercialization of Technology and Trade Secrets" to the NATO Science for Peace Workshop, Moscow, 2001; "Valuation of an Idea" to the Westlink Technology Commercialization Internship Program, April 2001; "On-Line Contracting" to the Informatics/Convergence Conference 2001; "Copyright" to the Technology Transfer Conference in Boston, 2001; and "Warranties in the Information Age" at the Best Practices Session of the 1999 and 2000 LES Annual meeting.

[back to top]

Mohan Rao, PhD
Mohan Rao, PhD,  is a Managing Director at Navigant Economics and an Adjunct Professor in the Department of Industrial Engineering and Management Sciences at the McCormick School of Engineering and Applied Science at Northwestern University. He specializes in intellectual property, antitrust, and financial economics.

Dr. Rao's intellectual property expertise includes valuation, business strategy, and the interplay between intellectual property and antitrust. He has experience in valuing early stage technologies, including in the pharmaceutical and biotechnology industries. He has studied market structure, competition, and performance of numerous pharmaceutical products, including pricing, marketing and promotion, clinical trials and regulatory approval, and competition policy.

Dr. Rao has served as an expert in U.S. and foreign courts and in arbitration proceedings. He has provided economic analysis in a wide range of intellectual property, antitrust, and financial markets litigation, on class certification issues, and has designed and conducted statistical surveys. He has evaluated commercial success of patented products, including in ANDA actions.

Dr. Rao teaches finance at Northwestern University and has previously taught courses in econometrics, game theory, and international trade as a professor at UCLA. He also teaches courses on valuing intellectual property at the Licensing Executives Society. He served as the Chair of the Valuation and Taxation Committee of the Licensing Executives Society.

Dr. Rao is a partner of Expression Therapeutics LLC, a biotechnology firm focused on advanced therapies for treating hemophilia A. He serves on the Board of Directors of the Children's Memorial Hospital in Chicago, on the Board of Trustees of the Rotary/One Foundation, the philanthropic arm of the 105-year old Rotary Club of Chicago, and is a member of the Economic Club of Chicago.

[back to top]

Robin Rasor
As Director of Licensing, Ms. Rasor oversees staff handling all functions of the licensing process at the University ranging from management and marketing of disclosures to developing and negotiating appropriate licensing terms for license agreements, and finally to maintaining and monitoring existing agreements.  Previously, Ms. Rasor was Director of Licensing at THE Ohio State University. Her primary focus was on technologies arising from life sciences research from the Colleges of Food, Agriculture and Environmental Sciences, Biological Sciences, Dentistry, Medicine, Pharmacy and Veterinary Sciences. In her previous ten years experience with Battelle Columbus Laboratories, a leading US contract research firm, Ms. Rasor traveled extensively to Japan and Europe for marketing and research programs.  Ms. Rasor has a MS in Genetics from The Ohio State University and a BS in Bacteriology and Zoology from Ohio Wesleyan University. Ms. Rasor is currently President-Elect of AUTM.

[back to top]

Matthew J. Raymond, Ph.D., M.B.A.
Director of Intellectual Property, Rush University Medical Center
Dr. Raymond is an experienced business development professional with the responsibility for technology transfer and intellectual property (IP) at Rush University Medical Center. Matt trained in technology transfer at the University of Virginia Patent Foundation and at The University of Chicago's Office of Technology and Intellectual Property. He is a co-founder of several companies including Sport Tech, Inc., a Virginia company that developed an instrumented arthrometer and Apicomplexan Therapeutics, a parasitology company. He has been actively involved in various stages of the formation of numerous other biotechnology companies. Matt initially worked as an Investigator in both discovery and clinical development for SmithKline Beecham Animal Health.

Dr. Raymond received his BS and PhD in Biochemistry/ Molecular Biology from the University of Wyoming and a MBA from the University of Virginia's Darden Graduate School of Business. He is a registered Patent Agent with the USPTO.

[back to top]

John Reid
John Reid is an experienced  business development leader with a supporting scientific career in pharma/biotech and drug discovery.  He specializes in strategic alliances and has built a strong reputation by leveraging critical science and business assets in alliances which have delivered over a dozen new drugs for clinical development.  He is responsible for early stage alliances and licensing in Neuroscience at AstraZeneca.   Previous roles include Director of Molecular Sciences at AstraZeneca,  Lab Head at the Glaxo Institute for Molecular Biology in Geneva, Switzerland, and Scientist at Genentech in San Francisco.  He is a graduate of UC Berkeley, (Ph D), UC Davis (B Sc), U. Penn-Wharton School (CPD), and Drexel (MBA).  He has authored over 30 publications, presented over 35 invited seminars, and was recently recognized as Co-Recipient for the "Deal of Distinction Award" from the Licensing Executive Society.

[back to top]

Thomas Rein
I am a partner in the Sidley Austin LLP Chicago office and have an active practice concentrated in the field of intellectual property.  I have been lead counsel in numerous high stakes cases, and have successfully tried cases in the courts, in arbitrations and in the International Trade Commission.  I represent clients in a number of industries. EDUCATION:  Harvard Law School (J.D., 1983, cum laude) PRACTICES:  Intellectual Property Litigation AREAS OF FOCUS:  Contract Litigation; ITC Section 337; Patent Litigation; Trade Secret and Unfair Competition Litigation; Trials

[back to top]

John F. Ritter
Director, Office of Technology Licensing at Princeton University.
Prior to coming to Princeton Mr. Ritter worked as a senior licensing professional at Rutgers University and held various sales and marketing positions in industry.  Mr. Ritter has a B.S. in Engineering from Rutgers, an MBA from Fairleigh Dickinson University, and a J.D. with Honors from Rutgers School of Law. A Registered  Patent Attorney, Mr. Ritter is licensed to practice law in New Jersey and Pennsylvania.

[back to top]

Art Rose
Arthur S. Rose is a partner in the law firm of Knobbe, Martens, Olson & Bear in the Irvine, California office and has been with the firm since 1982.  Art became a partner in 1984.  Art specializes in the preparation and negotiation of copyright, trademark and technology licensing agreements, resolution of disputes relating to intellectual property rights, patent procurement for medical devices and software, and copyright protection and enforcement.  Mr. Rose has been a speaker on licensing topics on several occasions.  Most recently Mr. Rose gave a talk titled "Managing Joint Ownership Rights IP" at the LES Orange County Chapter meeting.  Mr. Rose was a Patent Examiner at the U.S. Patent and Trademark Office working in the Medical Arts.  Mr. Rose obtained his juris doctorate, with honors, from George Washington University Law Center and clerked on the U.S. Court of Claims in Washington, D.C.  Mr. Rose has a Bachelor of Science degree in Engineering from UCLA. He has served on the Board

[back to top]

Jean Rumsfield
Jean Rumsfield Pharm.D. is Director of Business Development at Astellas US currently responsible for in-licensing oncology compounds.  October 2010 will mark Jean's ten year aniversary in business development  with Astellas/Fujisawa.  Prior to joining Astellas, Jean was a consultant with Hewitt Associates and The Mattson Jack Group.  Jean was also Vice President of Marketing and Business Development at GenDerm Corporation.  Jean received her B.S. in Pharmacy and Pharm.D. from the University of Illinois.

[back to top]

Pradip 'Pete' Sahu
Pradip 'Pete' Sahuis Intellectual Property Counsel for USG Corporation and its affiliates headquartered in Chicago. Pete has been with USG since 2006, and his practice focuses on all aspects of patent and trademark law, including litigation, clearance, licensing, agreements, prosecution, IP strategy, and counseling. He also leads the company's global trademark law practice. His work impacts USG's operations in North America, Europe, Latin America, Asia and the Middle East, and he has spent a considerable amount of time supporting the intellectual property efforts related to USG's China operations. He assists in managing and monetizing the company's global intellectual property portfolio related to the chemical and mechanical arts, and he has a special focus on transactional matters involving licensing and joint developments.

[back to top]

Fernando J. Sallés, Ph.D.
Dr. Sallés joined Merck through Merck's merger with Schering-Plough and is responsible for the neuroscience franchise research and development licensing strategy. The focus is to ensure end to end value growth and to make Merck the partner of choice. For the last 10 years he has been actively involved in strategy and business development activities both at biotechnology and pharmaceutical companies. Prior to Merck, he negotiated licensing, collaboration, and asset acquisition agreements for Schering-Plough and for Organon International.  Here he also directed financial assessments of opportunities and managed portfolio analytics for the company's pain portfolio. Previously, he headed up External Scientific Relations at Purdue Pharma and was Director of Business and Strategic Development at Cogent Neuroscience.  Fernando earned his PhD in molecular pharmacology and spent 9 years thereafter in academic/not-for-profit institutions. He is adjunct faculty at SUNY, Stony Brook.  He has been a member of LES since 2001.

[back to top]

Edward C. Saltzman
Ed is founder and President of Defined Health, a leading consultancy in business development and disease area strategy for the pharmaceutical industry. Since its founding in 1983, Defined Health has completed thousands of opportunity assessments and commercial forecasts of development stage projects for hundreds of corporate clients across the Big Pharma, Biotechnology and Specialty Pharma complex. Defined Health's length and breadth of experience in evaluating pipeline opportunities provides the firm with a unique and often unconventional spotlight on strategic issues confronting the industry, particularly with respect to the quality of the development pipeline and its implications for sustainability of established and evolving business models.

Ed is a noted speaker on industry strategy and was one of the earliest critics of the Pharma industry blockbuster business model and its over-dependence on in-licensing late-stage primary care blockbuster drugs to fuel growth. Ed was also one of the first to spot the limitation of the specialty pharma serial product acquisition model, and, as a result, he is much sought after for strategic guidance by specialty pharma and biotech companies facing sustainability challenges.
Ed is a member of the Licensing Executives Society and the New York Pharma Forum and is a graduate of New York University.

[back to top]

Michael R. Samardzija
Dr. Samardzija's practice focuses on representing clients in various technology-based transactions, including licenses, agreements for technology development, transfer, acquisition, joint development, collaboration, product development, strategic alliance and product distribution.  Dr. Samardzija's practice also focuses on the prosecution of patents in biotechnology and the lifesciences, specifically physiology, molecular biology, cell biology, immunology, pharmaceuticals, biologics and diagnostics.

Prior to joining Bracewell & Giuliani, Dr. Samardzija served as Director of Intellectual Property at The University of Texas M. D. Anderson Cancer Center's Office of Technology Commercialization.  Dr. Samardzija was also the sole in-house attorney at NeurogesX, Inc., a specialty biopharmaceutical company in San Carlos, CA focusing on pain.  Prior to this, he was an associate in the San Francisco office of Skjerven Morrill MacPherson LLP.

[back to top]

Larry Saret
Larry Saret is a member of the intellectual property practice group of Michael Best & Friedrich LLP. He conducts litigation, prosecutes domestic and foreign patents, trademark and copyright applications, and prepares intellectual property licenses, and other contracts. Mr. Saret's experience involves a wide variety of technologies, including computer and internet, automotive, medical, toys, electrical appliances, laboratory equipment and others. His industry experience is also varied, such as restaurant, financial, sports and entertainment, and retail merchandise. The variety and depth of Mr. Saret's practice has resulted in innovative solutions for many legal problems. Honors and Recognitions:  Mr. Saret has been repeatedly named one of "The Best Lawyers in America" and an "Illinois Super Lawyer" in the area of intellectual property law by various rating services.

[back to top]

Joshua Sarnoff
Joshua D. Sarnoff is an Associate Professor of Law at DePaul University College of Law, where he teaches patent law and other courses in the Center for Intellectual Property Law and Information Technology.  He is a registered patent attorney and a member of the bars of Washington DC and California, a former member of the Board of Governors of the Federal Circuit Bar Association, and a member of the boards of directors and advisory boards of various non-profit organizations.  He has written numerous articles and book chapters on patent law and has been involved in a wide range of intellectual property legal and policy disputes.  He has submitted testimony on domestic patent law reform bills, has filed numerous amicus briefs in the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit, has been a pro bono mediator for the Federal Circuit, and has been a consultant to the United Nations Conference on Trade and Development on international issues.

[back to top]

Andrew Schapals
Andrew S. Schapals, Senior Licensing Manager, Abbott Diagnostics – Andy has spent his entire professional career in Abbott Diagnostics and the last 18+ years in Licensing.  Over such time, Andy has executed hundreds of agreements of all types including commercial distribution, research collaborations, company acquisitions, asset divestitures, and of, course, licenses and options to intellectual property.  Such agreements have been with numerous Academic Institutions, Government Institutions and all sizes of Public Corporations and Private Companies.  Sales generated from incorporating technologies from such agreements are measured in the hundreds of millions as well as generating outlicensing  revenue in excess of $100 million since 2001.  Andy has a J.D. in Intellectual Property and a B.S. in Chemistry.

[back to top]

Aaron Schuchart
Aaron Schuchart, Principal of SEA Consulting Group, has over twenty-three years of experience in the biotechnology and energy industries.  His experience includes senior management positions - spanning business development, finance operations, and commercial organizations in large corporations and small firms.  Most recently, he was Vice President at Mendel Biotechnology where he led the development of Mendel's biofuels strategy and related business and product development functions.  Prior to Mendel, he held senior level positions at Amgen and Atlantic Richfield Company.  He has structured and negotiated many licensing and M&A deals in the biotech/bioenergy space and contributed to industry publications and presentations as both an advisor and speaker.  He has a BS from Texas Tech University, an MBA from the Anderson School at UCLA, is a CPA and a Certified Licensing Professional (CLP™).

[back to top]

Rachael S. Schwartz
Rachael S. Schwartz is a Senior Manager of ipCG. With over 10 years of management consulting experience in regional and international firms, Rachael guides clients who wish to align their intellectual property (IP) activities with their business strategy or use IP to gain leverage in transactions. Rachael ensures that resources invested in IP directly support corporate success, in the short and long terms. She also leads the development of IP Story materials that effectively communicate the value of IP, to increase investor confidence, foster strength in contract negotiations, and facilitate licensing and asset sale.

Recently, Rachael has been working on IP Story packages that seek to influence company value by conveying the significance of a company's intangible assets to financial markets. She has described this in her article, "How to Communicate the Real Value of Your Intellectual Assets to Wall Street." Additionally, she has been instrumental in developing the methodology of ipCG's IP Strategy practice, which focuses on creating a direct link between a company's highest level vision, mission, and goals and specific IP initiatives. This linkage can be accomplished in all organizations, from small single-product companies to large multi-division, global conglomerates.

Prior to joining ipCG, Rachael was a strategy consultant at DiamondCluster International, a consulting firm that focuses on the intersection of new technology and business strategy. While her primary focus in 10 years of consulting and marketing has been strategy development, she has also helped companies achieve their strategic objectives through business plan development, financial analysis, feasibility studies, organizational development, process reengineering, and marketing tactics.

Rachael received an MBA in Strategic Management and Marketing from the Wharton School of Business of the University of Pennsylvania and a BA in Architecture from the University of Pennsylvania.

[back to top]

Katherine (Kate) Shore
Her focus is the application of IP strategy and management methodologies for clients, particularly consumer products companies, including integrating brand characteristics and consumer research into IAM processes and maximizing internal innovation via the application of creativity and targeted invention methodologies. Prior to ipCG, Kate sourced and screened business opportunities for consumer products companies at Technology Catalysts International. Her background is in biotechnology, where she has conducted scientific research at Stryker Biotech and deCode Genetics. She earned her BS degree in Biotechnology with a Chemistry concentration from Worcester Polytechnic Institute.

[back to top]

Ida C. Shum
Ida C. Shum is a Business Development Executive for Lawrence Livermore National Laboratory. She is responsible for the commercialization of technologies in the areas relating to biotechnology, chemistry and materials. Previously, Ida was at the Idaho National Laboratory commercializing technologies covering national security, industrial processes and materials. She has spent the last six years creating technology partnerships with industrial, private entities, and academic partners. Ida is currently the Federal Laboratory Consortium (FLC) Far West Region's Regional Coordinator. In 2007, she was recognized as the Far West Region's Outstanding Laboratory Representative.

Ida earned her B.S. in Biochemistry from UCLA (1999); her J.D. from the University of Notre Dame (2003). While at Notre Dame Law School, Ida served as the Editor-in-Chief of the Journal of Legislation. She is admitted to practice before the California State Bar and the United States Patent and Trademark Office.

[back to top]

Lauren Silverman
Dr. Lauren Silverman is a Managing Director of the Novartis Option Fund in Cambridge, MA, USA.  Prior to joining the Option Fund she was Global Head of Oncology Research Operations for Novartis. Previously, Lauren spent much of her career in Licensing & Business Development, first at OSI Pharmaceuticals and later at Pfizer with responsibilities in the areas of CNS, ophthalmology and oncology. Lauren was also a Director of Strategic Alliances and Head of Cell Biology where she led multiple research teams after having been a founding scientist of Cadus Pharmaceuticals. Lauren was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and Princeton University and earned her Ph.D. in molecular biology from the University of Utah. Lauren currently serves on the Boards of Directors of AnchorTherapeutics, Proteostasis Therapeutics, Cequent Pharmaceuticals, Viamet Pharmaceuticals, Inc. Pulmatrix Inc. and Ra Pharmaceuticals, Inc. 

[back to top]

Robin Sitver, CLP™
Robin Sitver is Executive Director, Business Development at JJCCI.  She is responsible for global business development for the topical healthcare franchise that includes Band-Aid Brand Adhesive Bandages, Neosporin, Purell, BenGay and a number of other major brands. She is also responsible for business development for OTC eye care. She has responsibility for acquisitions, divestitures, patent licenses and trademark licenses.

Robin joined JJCCI with the acquisition of Pfizer Consumer Healthcare in 2006. She was responsible for approximately $1 billion in FTC mandated divestiture transactions which included Zantac, Unisom, Kaopectate and Cortizone.  She recently divested an additional 10 brands including Stim-U-Dent and Emetrol to three different buyers.

Robin joined Pfizer in 1979 in the Pharmaceuticals Division and held a variety of positions in finance, systems, marketing and international operations in the Pharmaceuticals and Animal Health Divisions before joining Pfizer Consumer Healthcare in 2001. She has been involved with numerous license, acquisition and divestiture transactions at Pfizer. She was the lead division finance person for the $1.45 billion acquisition of SmithKline Beecham Animal Health. She negotiated the acquisition of Purell in 2004 and completed transactions that led to the launches of Rolaids Softchews, Benadryl Fastmelts, Sudacare Vapor-Plugs and Visine Pure-Tears.

Robin is an active member of LES. Robin holds an MBA from the Wharton School of the University of Pennsylvania and a BA in Computer Science from Brandeis University.

[back to top]

Gene Slowinski
Gene Slowinski is the Director of Strategic Alliance Research at the Graduate School of Management, Rutgers University and Managing Partner of the Alliance Management Group, a consulting firm devoted to the formation and management of strategic alliances, mergers and acquisitions. Prior to forming the Alliance Management Group, he held management positions at AT&T Bell Laboratories, and Novartis Corporation. In addition to a Ph.D. in Management, Gene holds an MBA, and a Masters Degree in the sciences. He is a member of Los Alamos National Laboratory's Technology Commercialization Advisory Board  For the last 25 years Dr. Slowinski has consulted and conducted research on the formation and management of strategic alliances, joint ventures, mergers, and acquisitions. An author and lecturer, Gene has presented his work to The Conference Board, The Licensing Executives Society, The Industrial Research Institute, and The American Electronics Association. His articles on managing strate

[back to top]

Craig Smith
Craig Smith is Sandia National Laboratories Commercial Licensing Manager for Emerging Technologies.  Mr. Smith's primary focus is developing key commercialization strategies for the Department of Energy's premier Combustion Research Facility, specializing in the fields of Renewable Energy Research, Industrial Processes, Engine Emissions and Hydrogen Fuel Cell Development.  In addition, Craig is responsible for the commercial and open source licensing of all software related intellectual property, software development for the National Cyber Security program, and all commercial opportunities emerging from Sandia's Distributed Information Systems Laboratory complex.   Craig has extensive experience in direct and network marketing of a broad range of emerging  technologies, having negotiated and written hundreds of license agreements based on Department of Energy patents and copyrights.   Craig brings to Sandia's Technology Commercialization Office over 25 years of contract negotiation experience.

[back to top]

Jeff Snell
Mr. Snell focuses primarily on assisting clients with financial and economic issues in the context of intellectual property (IP) disputes and transactions. Mr. Snell has served as an expert witness in patent infringement and commercial litigation matters, advised clients in the negotiation of financial terms of IP transactions, assisted in the settlement of patent infringement litigation, and valued IP in a number of contexts.  In the context of serving as a financial advisor in IP transactions, Mr. Snell has assisted clients with economic and financial issues in the negotiation of patent license agreements.  His experience has ranged from negotiating financial terms to providing flexible valuation models in support of clients' negotiation efforts.  He builds complex flexible valuation models, which typically include decision trees, Monte Carlo analysis, and sensitivity analysis.

[back to top]

James Sobieraj
James R. Sobieraj has over 28 years of experience in the enforcement, defense and licensing of intellectual property rights.  He has represented large, mid-sized and small companies in a variety of technologies including analog and digital electronics, microprocessors, electrical and optical connectors, avionics, pharmaceuticals, medical devices, and various consumer goods.  Mr. Sobieraj received degrees in electrical engineering and law from the University of Michigan.  He is registered to practice before the USPTO, and has appeared before numerous federal and state courts, including the CAFC.  He has experience as trial counsel in cases involving patent infringement, ownership of patent rights, license disputes, misappropriation of trade secrets, trade dress infringement, and unfair competition.  Mr. Sobieraj is a past president of the Licensing Executives Society (USA & Canada), and currently serves as counsel to the Board of Directors of LES International.

[back to top]

Vanita Spaulding
Vanita M. Spaulding, MBA, CFA, ASA, is the Managing Director of Valuation leading the Western Region for Ceteris, a global independent consulting firm specializing in transfer pricing, intellectual property and valuation services.  Vanita has appeared as an expert witness before the Superior Courts throughout Southern California and the American Arbitration Association.   Her 25 years of expertise encompasses a diverse background of valuation projects including intellectual property analyses, allocation of purchase price and impairment testing, common stock valuation and share-based compensation valuation, fairness and solvency opinions, litigation support, pre-acquisition financing, merger and acquisition pricing, federal estate tax and gift tax, dissident stockholders, breach of contract, lost profits, ESOP formation and compliance, and eminent domain.   Vanita has also been a lead course instructor/developer with ASA for more than 15 years for the four core accreditation courses.

[back to top]

Susan L. Stoddard, Ph.D., CLP™
Dr. Stoddard is Senior Licensing Manager in Mayo Clinic's Office of Intellectual Property, specializing in biotechnology.  She has been with Mayo Clinic for sixteen years, including work with the Office of Strategic Alliances.  Prior to joining Mayo, Dr. Stoddard was a tenured Professor of Neurosciences at Indiana University School of Medicine. 

Dr. Stoddard received her A.B. from Vassar College, her Ph.D. from Rutgers University, and did a postdoctoral fellowship at the College of Medicine and Dentistry of New Jersey.

[back to top]

Philip Strassburger
Philip C. Strassburger,  Vice President, Intellectual Property Counsel Purdue Pharma L.P.  Philip Strassburger joined Purdue Pharma L.P. in 1999.  Before joining Purdue, he served as Senior Patent Counsel at Pfizer, Inc., and as an associate at the law firms of Hedman Gibson and Bryan Cave LLP in New York.  Prior to his legal career, Mr. Strassburger practiced as a Chemical  Engineer in The Netherlands.  Mr. Strassburger has worldwide responsibility for intellectual property prosecution and litigation, and has negotiated numerous acquisitions, licenses and patent settlements throughout the world.  In the United States he is also responsible for antitrust, transactional and regulatory legal matters.  Mr. Strassburger received his B.S. degree in Chemical Engineering and his B.A. in Philosophy from Tufts University, and a Juris Doctorate degree from the University of Connecticut.  He is admitted to practice in New York and Connecticut, as well as the U.S. Patent and Trademark Of

[back to top]

Nancy Sullivan
Nancy Sullivan,   Director of the University of Illinois at Chicago's Office of Technology Management.    Ms. Sullivan serves as the Director of the Office of Technology Management (OTM) at the University of Illinois at Chicago.  As Director, she leads a team of nine professionals responsible for the identification, protection, marketing and licensing of intellectual property arising from the more than $300 million in research conducted on the campus. Ms. Sullivan also works with a wide range of campus, corporate and community partners, furthering the office's mission to encourage innovation, enhance research and facilitate economic development.  Prior to joining the OTM, Ms. Sullivan was Senior Director of Business Development for KeraCure, an early-stage biotechnology company currently in clinical trials of a cell-based device for treatment of chronic wounds. Previously, Sullivan was director of the Entrepreneurial Life Sciences Initiative at Northwestern University.   Ms. Sullivan earned her MBA from Northwestern University's Kellogg School of Management and a Master's in Biotechnology, also from Northwestern. She earned her bachelor's degree in Business Administration from Loyola University.

[back to top]

Elliot Swan
As Director of Technology Licensing for Raytheon Company, Elliot is responsible for identifying commercial uses for the company's defense-inspired technologies and driving commercial licensing deals to generate supplemental income for the company. Prior to Raytheon, Elliot's career spanned 28 years in non-defense businesses where he played leadership roles in product development, product management, M&A and venture capital. Elliot was formerly a Managing Director for TD Capital Ventures and Director of Strategic Investments for Intel Capital. He also served various marketing and business development roles during an 18 year career at the Intel Corporation. Elliot holds an MBA from the University of Chicago and a BSEE degree from Princeton University.

[back to top]

Christopher G. Talbot
Christopher G. Talbot is Senior Director of the Strategic Licensing Group at Applied Materials. Applied Materials' Strategic Licensing Group (SLG) was formed in early 2006 as a complement to core licensing activities in order to monetize untapped value in Applied Materials' technology and IP portfolios which include >4000 US patents.  SLG has built a pipeline of over 30 technologies, has closed 8 licenses to date and has another 4 in the final stages of negotiations.  Dr. Talbot has been instrumental in building the SLG team.  He joined Applied Materials in 2001 as part the acquisition of Schlumberger's E-beam Inspection unit, which he founded.  Prior to his current assignment, he was Senior Director, New Business, Process Diagnostics and Control.  Talbot holds BS and Ph.D. degrees in Physics from the University of Reading, UK, and has been a registered US Patent Agent since 2000.  Talbot has 19 US patents, has authored ~ 40 papers and has been a member of LES since 2005.

[back to top]

Richard Lawton Thurston, Ph.D. 
Dr. Richard Thurston is Vice President, and General Counsel of TSMC.

Before joining TSMC, Dr. Thurston was a Partner at Haynes and Boone, Dallas, Texas.  Previously, he was the Regional Counsel, Asia Pacific and Vice President, Corporate Staff, Assistant General Counsel at Texas Instruments (1984-1996).  His legal experiences include: foreign trade/investment, M&A, technology transfer, general corporate matters, intellectual property rights issues, commercial transactions, strategic alliances, and dispute resolution.

Dr. Thurston graduated Cum Laude with a B.A. degree in History from Alma College, and an M.A. degree and a Ph.D. degree in East Asian Studies from the University of Virginia, U.S.A.  His J.D. degree is from Rutgers School of Law (New Jersey).  Dr. Thurston also studied law at Soochow University, (Taiwan), while researching his Ph.D. dissertation: Civil Law Reform in China, 1906-1930.  Dr. Thurston has also taught courses at: Southern Methodist School of Law/School of Management; University of Texas, Dallas; Soochow University, National Chiao Tung University and National Chen-Chih University.  Dr. Thurston has been active in numerous community affairs in the U.S., Japan and Taiwan.

[back to top]

David Tollen
David Tollen is the author of the American Bar Association's handbook on technology contracts (www.TechContractsHandbook.com). He is one of the founding partners of Adeli & Tollen LLP (www.AdeliTollen.com), an IP and IT boutique with offices in San Francisco, the Silicon Valley, and Los Angeles. His practice focuses on information technology and IP transactions, including software licensing, as well as Internet and open source law. Mr. Tollen is also the founder of Tech Contracts Chalkboard (www.TechContracts.com), which provides training on negotiating and drafting technology agreements, for both businesspeople and lawyers. In the past, Mr. Tollen has served as General Counsel of a publicly traded software company, as Vice President of Business Development with a technology startup, and as an associate with a global law firm. He graduated with honors from Harvard Law School and received an Ll.M. from Cambridge University in England.

[back to top]

Steven Tregay, Ph.D.
Prior to joining FORMA, Steven Tregay was a Managing Director for the $200M Novartis Option Fund. He led the fund's investments in and served on the Board of Directors of FORMA Therapeutics, Adenosine Therapeutics (sold: CLDA) and Cequent Pharmaceuticals. Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances-Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team who were responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research. He received his Ph.D. and M.S. in organic chemistry from Harvard University and a B.S. from Davidson College.

[back to top]

Pannie Trifillis
Pannie Trifillis, Ph.D. CA-AM is Associate Director of Alliance Management (AM) at PTC Therapeutics, Inc., where she established and heads the AM department since 2006. Pannie's group maintains a high level of performance across a portfolio of four strategic alliances with companies like Genzyme, Celgene, Merck, and Roche, along with two collaborations with the SMA Foundation and PPMD. Prior to her involvement in AM, Pannie was the first scientist at PTC where she established the discovery team and initiated a number of programs including the nonsense readthrough program which yielded ataluren, PTC's most advanced small molecule which is now in registration-directed studies. Pannie has authored 14 publications and patents. She holds a Ph.D. in Molecular Biology and Human Genetics from the University of Pennsylvania and a BA in Biochemistry from Wellesley College. Pannie is ASAP CA-AM certified and serves on the ASAP BioPharma Council Executive Committee.

[back to top]

Jan Twombly
Janice M. Twombly, CSAP, is President of The Rhythm of Business, Inc., a research and consulting group specializing in collaborative business - the organizations, business models, management and ways of working to innovate and succeed through collaboration. In this role she has engaged with global, cross industry and cross sector collaborations. Her emphasis is on scientific and technically intensive industries, such as life sciences and energy, as well as complex issues related to economic development that are as diverse as hunger, fostering entrepreneurship, and growing R&D intensive investment. Twombly holds the Certified Strategic Alliance Professional (CSAP) designation from the Association of Strategic Alliance Professionals.  She serves on the Executive Committee of the Association's Board of Directors as Chairperson of the Marketing Committee. She also serves on the Global Summit Planning Committee and is Chairperson of the Biopharm Council Summit Planning Committee.

[back to top]

Larry Udell
Serves as Executive Director of California Invention Center - founded with a Federal Grant in 1995
Center For New Venture Alliance - founded in 1990 as part of Cal-State University
Intellectual Property International, Ltd. - created in 1998 with 50 colleagues in all parts of the world

Has devoted a half-century to entrepreneurial endeavors, lecturing and teaching as a Professor of New Ventures since 1982

Left his last employer in March of 1964

Has created more than thirty corporations (none of which ever went bankrupt)

Teaches accredited courses in New Ventures & Entrepreneurship at leading universities throughout the U. S. and Canada

Lectures throughout the U. S. for the PTO and clients, plus overseas for the World Intellectual Property Organization  (part of the United Nations)

Consults to Fortune 500 companies, small firms, new ventures, and qualified  teams thinking of going into business

Has been quoted in: Time Magazine, the Wall Street Journal, New York Times, USA Today,  Associated Press, The World Almanac, Washington Post, the Los Angeles Times, Forbes Magazine, etc.

[back to top]

Ramani Varanasi, MS, MBA
Ms. Ramani Varanasi currently serves as Vice President and Head of Business Development at RXi Pharmaceuticals, a discovery stage biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases.

Ms. Varanasi has over 15 years experience working with premier biotech companies in structuring, negotiating and executing successful strategic alliances, R&D collaborations & partnerships, licensing agreements and M&A transactions. Her corporate and business development experience includes 9 years at Millennium Pharmaceuticals as Director, Business Development, followed by a position as Director of Corporate Development at Momenta Pharmaceuticals. Most recently, she was the Head of Business Development at Archemix Corporation, and led the strategy and execution of several strategic technology, research collaboration and product alliances, including the deal that resulted in the creation of the partnership with Merck Serono, a multi-year alliance with a deal value greater than $600M. Her broad experience in the branded and generic pharmaceutical product space has enabled her to execute several deals with total value in excess of $1B in the past two years, alone.  Ms. Varanasi holds a B.Sc. and a M.Sc. from McGill University in Microbiology & Immunology and Biochemistry, respectfully, and an MBA in General Strategy from Northeastern University.

[back to top]

Edna Vassilovski
Edna Vassilovski is a partner in the Minneapolis office of Stoel Rives.  As an IP strategist, she assists clients pragmatically and creatively use IP to achieve company goals.  Edna also provides: (1) traditional IP counsel including patent preparation and prosecution, global portfolio management, trade secret evaluation and program development, and all variety of IP opinions; (2) IP business opportunity assessments; and (3) agreement drafting and negotiation services that enable entities to work collaboratively to advance technology. As a former in-house counsel at Cargill, she has a special interest in biofuels and bio-based chemicals, and has a considerable practice in this area.  Her significant technical experiences also encompass food, nutraceuticals, pharmaceuticals, cosmetics, biotechnology, semiconductors, medical and mechanical devices.  Edna was educated at Stanford University (BA Chemistry), Harvard University (MA Chemistry) and Columbia University (JD). 

[back to top]

Allen Vaughn
Allen Vaughn is Manager of Intellectual Property Strategy and Licensing for Lockheed Martin Missiles and Fire Control which encompasses approximately 20% of the corporation IP assets.  As such he is responsible both for the portfolio management and all licensing transactions.  He brings over 30 years of experience in many facets of the business to include program management, domestic and international business development and strategic planning to his effort concerning licensing transactions.

[back to top]

Anthony P. Venturino
Anthony P. Venturino is a registered patent attorney with corporate and law firm experience as a chemical engineer with Exxon, is a licensed professional engineer in New Jersey, and was a patent counsel with U.S. Surgical Corporation. He has prepared numerous US and PCT patent applications, trademark applications and opinions, and participated in major litigations. Mr. Venturino also has been responsible for a number of complex activities including negotiating and drafting agreements, conducting due diligence for multi-million dollar technology acquisitions and counseling senior management on intellectual property issues.

Mr. Venturino's fields of technical expertise include chemistry, catalysts, oil, gas and coal processing, materials science, metallurgy, polymers, surfactants, pharmaceuticals, biotechnology, and medical devices. Mr. Venturino has published a number of articles in leading journals such as the Journal of the Patent and Trademark Office Society (U.S. Patent and Trademark Office), IDEA (Franklin Pierce University), GRUR Int'l (Max-Plank Institute), Patent Law Annual (Southwestern Law Institute) and Chemical Engineering magazine (McGraw-Hill). He has lectured extensively on U.S. patent practice both in the United States and abroad. He is ranked as "AV" from Martindale Hubbell Law Directory, the highest rating given to participating attorneys. Over the years, Mr. Venturino has been recognized by his peers as a top lawyer in his field.

[back to top]

Erik Verbraeken
Associate Director of Contracts and Business Law Division of IFP New Energy ; Contracts & Land Manager of IFP Technologies (Canada) Inc.; Contract Manager of IFP Services. Areas of responsibility : Exploration & Production contracts ; Powertrain contracts ; Design & build contracts. Prior presentation LES 2009 San Francisco : Antitrust Implications of Royalty Deals

[back to top]

John Veschi
As the Chief Intellectual Property Officer at Nortel Networks, John is leading the company's intellectual property organization through a complex multi-jurisdictional bankruptcy process.  Nortel's rich research and development history dating back to the late-1800s yields a diverse patent portfolio relating to high tech, telecom, internet and other technical fields.  Prior to joining Nortle, John had many years of experience running P&L intellectual property businesses.  He was the General Manager of LSI's Intellectual Property Business, which had been Agere's IP Business prior to the Agere/LSI merger.  Based in part on Bell Labs technology, these businesses generated annual IP revenue in the hundreds of millions of dollars, and have a reputation for thoughtful, strong, technology-based assertion and licensing practices.  A former Army officer, John has a BS in Electrical Engineering from Lafayette College, an MBA from GWU and a JD from the University of Maryland.

[back to top]

Dr. James Vlazny
Dr. James Vlazny has 30 years of experience in the pharma/biotech licensing field, and has successfully found products and partners and negotiated licensing agreements for numerous companies and clients during this time. He is the developer of the unique PLAN Licensing Process, which involves the four basic steps of Licensing: Preparation, Looking, Analyzing, and Negotiating.
He is a long-standing member of the Licensing Executives Society where he presently serves as Co-Chairman of the LES Mentoring Committee, teaches different modules of the LES Professional Development Series on licensing, and has served as past Co- Chairman of the Chicago Chapter of LES. Dr. Vlazny has written articles, chaired workshops, and given many presentations on various aspects of pharmaceutical and biotech licensing around the world.

[back to top]

Glenn Von Tersch
Mr. Von Tersch practices in the Palo Alto office of TIPS Group.  Mr. Von Tersch specializes in counseling of clients in the high technology and consumer products spaces.  This includes working with clients in early-stage formation of companies, advising on and negotiating deals of various types (such as technology transactions), assisting with intellectual property strategy, and providing counseling in related areas such as internet issues.  Mr. Von Tersch has a background as an engineer in the high technology sector and as an attorney practicing in transactions, litigation and prosecution of intellectual property.

[back to top]

Angela Wenninger
Angela is a German attorney-at-law since 2006. Her practice focuses on litigation and prosecution of IP rights in the field of trademark law, as well as design and domain law. She advises and represents both multinationals and SMEs in various fields of trade and industry, with an emphasis on the protection of brands and trademarks for technology. Angela is currently involved in litigation in a series of trademark infringement proceedings before the German courts. She also regularly handles preliminary injunction and boarder seizure proceedings. Angela has been with Hoffmann Eitle since 2006.

[back to top]

Brandon Williams
Brandon Williams' career spans industries from software and banking to infrastructure development and engineering. His observations of the IP placement market revealed its lack of structure or investment methodology.  Prior to IgniteIP Brandon was involved with a number of companies including positions as the CFO of an international telecommunications infrastructure developer; a founding manager of a middleware software company; an investment banker with Citibank in New York; and a nuclear engineer and submarine officer with the U.S. Navy. Brandon has a significant network of investors and high-level industry contacts that facilitate the IgniteIP business model. Brandon holds a BA in Liberal Arts from Pepperdine University and an MBA from the Wharton School of the University of Pennsylvania. He also is a former member of the Board of Trustees for the Seattle Opera.

[back to top]

Katharine Wolanyk
Katharine Wolanyk is President of Soverain Software and one of its founders.  With degrees in engineering and law, Ms. Wolanyk has 20 years of experience spanning the business, legal and technology arenas.  Under her leadership, Soverain's intellectual property has been enhanced and its flagship product Transact reinvigorated.  Soverain has successfully licensed its pioneering patent portfolio to a number of the largest e-tailers.  Prior to launching Soverain in 2003, Ms. Wolanyk was Senior Vice President of Corporate Development for a publicly-traded software company.  Before that, Ms. Wolanyk was in private practice with Latham & Watkins, and she began her career as a systems engineer for Hughes Aircraft Company.  Ms. Wolanyk earned her J.D. from the University of Chicago Law School and her B.S. in Engineering from Michigan State University.

[back to top]

Mary  Woodford
Mary Woodford heads Cornerstone Researh's intellectual property practice. She specializes in applying financial and operational analyses to damages assessments in complex commercial litigation, with an emphasis on intellectual property disputes. In addition to her work in patent, trademark, copyright, and trade secret matters, Ms. Woodford has directed and developed damages analyses in breach of contract, class action, and other commercial disputes. For nearly twenty years, she has consulted to clients in numerous industries, including telecommunications, electronics, semiconductor, cable television equipment, hardware and software, medical devices, pharmaceutical, and other industrial and consumer products. Ms. Woodford has testified at trial and depositions in federal and state courts as well as in arbitration. Before joining Cornerstone Research, Ms. Woodford was a director in PricewaterhouseCoopers' Financial Advisory Services practice.

[back to top]

Don Wright
Don Wright brings more than 20 years of information technology, product development, and operations experience to AssureRx. Don has served as vice president of product development at Attachmate, leading a 450 person worldwide product development organization. Don has also served as CTO for Spotlight Solutions, a leading provider of retail pricing and revenue optimization products, as well as working on the merger with ProfitLogic, which was sold to Oracle. Don also served as vice president and CIO for Domin-8 Enterprise Solutions, overseeing web-based product offerings, which grew to over six million units under management. Most recently, Don was co-founder and CTO of SaaS Capital, a specialty finance company serving the SaaS software market.

[back to top]

Junichi Yamazaki
Junichi Yamazaki is a senior partner of Miyake & Yamazaki in Tokyo, Japan, a member of Tokyo Bar Association and Japan Patent Attorneys Association.  He practices law with emphases on intellectual properties and high-tech venture business strategies, and represents and advises wide variety of clients in IP litigations and negotiations involving patents, trademarks, designs, trade secrets, and various technology issues and unfair competition disputes.  His present positions include President, LES Japan and Statutory Auditor of Music Publishers Association of Japan. He is former President of Japan Intellectual Property Arbitration Center (JIPAC), Chair of Intellectual Property Committee of Inter-Pacific Bar Association (IPBA). He has served as instructor of the special training course for representation in IP infringement litigations organized by Japan Patent Attorneys Association since 2004.   

[back to top]

Jordan Yarett
A partner in the Corporate Department and co-head of the Finance Group, Jordan E. Yarett has over 25 years of experience as a financing lawyer focusing on structured finance and securitization transactions. In 2007 The American Lawyer selected Mr. Yarett as a 'Dealmaker of the Year' for his representation of Lehman Brothers Inc., the lead underwriter and sole structuring agent for Dunkin' Brands Inc. in its complex $1.7-billion whole-business securitization. He was also selected as a Lawdragon 500 Leading Lawyer in America for conceiving and executing the Dunkin' Brands transaction. He has been repeatedly recognized by Chambers USA and Legal 500 US as a leading capital markets lawyer. Mr. Yarett is a Lecturer in Law at the University of Pennsylvania Law School and has written a chapter on derivatives litigation for Derivative Risk and Responsibility and two chapters in Securitization Legal and Regulatory Issues published by American Lawyer Media, Inc.

[back to top]

Carolyne Zimmermann
Carolyne Zimmermann is the Head of Negotiations and Alliance Management at Novartis Pharmaceuticals. Her career encompasses over 15 years of business development and licensing expereince in the pharmaceutical and biotech industry and includes a variety of transactions including: product acquisitions and divestments, in- and out-licensing transactions, technical development and contract manufacturing agreements. Angela Bylancik is a Global Alliance Manager with Novartis Pharmaceuticals, Inc. Angela has been at Novartis since 2001 and was previously with Hoffmann-LaRoche, Inc. for 17 years. Angela has held positions in Pharmaceutical Sales, Market Research, New Product Marketing, In-line Marketing and Business Development and Licensing. During her career in Pharma she has been involved in all phases of BD&L from Asset Evaluation and Forecasting, Negotiation, and Alliance Management.

[back to top]